

Best Available Copy



2004/0001539



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 08 JUN 2004


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed


Dated

R. Mahoney

27 May 2004

07MAY03 E805322-1 002934
P01/7700 0-00-0310401.5**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

 Cardiff Road
 Newport
 South Wales
 NP10 8QQ

1. Your reference 101046-1

2. Patent application number
(The Patent Office will fill in this part)

0310401.5

07 MAY 2003

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*
 AstraZeneca AB
 SE-151 85 Södertälje
 Sweden

7822448003

Patents ADP number *(if you know it)*

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

THERAPEUTIC AGENT

5. Name of your agent *(if you have one)*

Brian Steele TAIT

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

 AstraZeneca UK Limited
 Global Intellectual Property
 Mereside, Alderley Park
 Macclesfield,
 Cheshire SK10 4TG

798473001

Patents ADP number *(if you know it)*6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country

Priority application number
*(if you know it)*Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
*(day / month / year)*8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

- a) *any applicant named in part 3 is not an inventor, or*
- b) *there is an inventor who is not named as an applicant, or*
- c) *any named applicant is a corporate body.*

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	61
Claim(s)	9
Abstract	1
Drawing(s)	3 + 3

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Jennifer Bennett, Authorised Signatory

Date 06/05/03

12. Name and daytime telephone number of person to contact in the United Kingdom

Shirley Douglas - 01625 510057

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

THE THERAPEUTIC AGENT

The present invention relates to the use of an anti-angiogenic agent in combination with an inhibitor of the Src family of non-receptor tyrosine kinases in the manufacture of a medicament for use in the production of an anti-angiogenic and an anti-cancer effect, to a method for providing an anti-angiogenic and an anti-cancer effect by the administration of an anti-angiogenic agent and an inhibitor of the Src family of non-receptor tyrosine kinases, to a combination product comprising a particular anti-angiogenic agent and a particular inhibitor of the Src family of non-receptor tyrosine kinases and to a pharmaceutical composition comprising a particular anti-angiogenic agent and a particular inhibitor of the Src family of non-receptor tyrosine kinases. In particular, the present invention relates to the use in combination of an anti-angiogenic agent that is an inhibitor of the vascular endothelial growth factor (hereinafter VEGF) receptor tyrosine kinases together with an inhibitor of the Src family of non-receptor tyrosine kinases. The invention is useful in a method for the treatment of diseases associated with angiogenesis and in a method for the treatment or prophylaxis of cancer, particularly of solid tumour disease.

Current options for treating cancer include surgical resection, external beam radiation therapy and/or systemic chemotherapy. These are partially successful in some forms of cancer but are less successful in others. There is a continuing need for new therapeutic treatments for treating cancer.

Inhibition of VEGF Receptor Tyrosine Kinases

Normally, angiogenesis, the process of forming new blood vessels, plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. However, undesirable or pathological angiogenesis has been associated with a number of disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan *et al.*, Trends in Pharmacol. Science, 1995, 16, 57-66; Folkman, Nature Medicine, 1995, 1, 27-31).

Angiogenesis is stimulated via the promotion of the growth of endothelial cells. Several polypeptides with *in vitro* endothelial cell growth promoting activity have been identified including acidic and basic fibroblast growth factors (aFGF and bFGF) and VEGF. By virtue of the restricted expression of its receptors, the growth factor activity of VEGF, in contrast to that of aFGF and bFGF, is relatively specific towards endothelial cells. Recent evidence indicates

that VEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman *et al.*, Endocrinology, 1993, 133, 848-859; Kolch *et al.*, Breast Cancer Research and Treatment, 1995, 36, 139-155) and vascular permeability (Connolly *et al.*, J. Biol. Chem., 1989, 264, 20017-20024). Alteration of vascular permeability is also thought to play a role in both normal 5 and pathological physiological processes (Senger *et al.*, Cancer and Metastasis Reviews, 1993, 12, 303-324).

Receptor tyrosine kinases (RTKs) are important in the transmission of biochemical signals across the plasma membrane of cells. These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a 10 segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, a number of distinct RTK subfamilies, defined by amino 15 acid sequence homology, have been identified. One RTK family comprises the *fms*-like tyrosine kinase receptor Flt-1, the kinase insert domain-containing receptor KDR (also referred to as Flk-1) and the *fms*-like tyrosine kinase receptor Flt-4. Two of these related RTKs, namely Flt-1 and KDR, have been shown to bind VEGF with high affinity (De-Vries *et al.*, Science, 1992, 255, 989-991; Terman *et al.*, Biochem. Biophys. Res. Comm., 1992, 187, 1579-1586). 20 Binding of VEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins and calcium fluxes.

VEGF is a key stimulus for vasculogenesis and angiogenesis. This cytokine induces a vascular sprouting phenotype by inducing endothelial cell proliferation, protease expression and migration, and subsequent organisation of cells to form a capillary tube promoting 25 formation of a hyper-permeable, immature vascular network which is characteristic of pathological angiogenesis. It has been shown that activation of KDR alone is sufficient to promote all of the major phenotypic responses to VEGF, including endothelial cell proliferation, migration and survival, and the induction of vascular permeability.

Accordingly, antagonism of the activity of VEGF is expected to be beneficial in the 30 treatment of a number of disease states that are associated with angiogenesis and/or increased vascular permeability such as cancer, especially in inhibiting the development of tumours.

Src Non-Receptor Tyrosine Kinase Inhibition

In recent years it has been discovered that cells may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene *i.e.* a gene which, on activation, leads to the formation of malignant tumour cells. It is known, for example, that several oncogenes 5 encode tyrosine kinase enzymes and that certain growth factor receptors are also tyrosine kinase enzymes. The first group of tyrosine kinases to be identified arose from such viral oncogenes, for example pp60^{v-Src} tyrosine kinase (otherwise known as v-Src) and the corresponding tyrosine kinases in normal cells, for example pp60^{c-Src} tyrosine kinase (otherwise known as c-Src).

10 The Src family of non-receptor tyrosine kinases is located intracellularly and is involved in the transmission of biochemical signals such as those that influence tumour cell motility, dissemination and invasiveness and subsequently metastatic tumour growth. Members of the Src family include *inter alia* c-Src, c-Yes, c-lck and c-Fyn.

It is further known that the Src family of non-receptor tyrosine kinases is highly 15 regulated in normal cells such that, in the absence of extracellular stimuli, the kinases are maintained in an inactive conformation. However, some Src family members, for example c-Src tyrosine kinase, are frequently significantly activated (when compared to normal cell levels) in common human cancers.

Accordingly it has been recognised that an inhibitor of such non-receptor tyrosine 20 kinases should be of value as a selective inhibitor of the motility of tumour cells and as a selective inhibitor of the dissemination and invasiveness of mammalian cancer cells leading to inhibition of metastatic tumour growth. Thus the predominant role of c-Src non-receptor tyrosine kinase is to regulate cell motility which is necessarily required for a localised tumour to progress through the stages of dissemination into the blood stream, invasion of other tissues 25 and initiation of metastatic tumour growth. c-Src kinase is involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells.

Accordingly Src kinase inhibitors are of value as anti-tumour agents, in particular as 30 selective inhibitors of the motility, dissemination and invasiveness of mammalian cancer cells leading to inhibition of metastatic tumour growth. Particularly, Src kinase inhibitors are of value as anti-invasive agents in the containment and/or treatment of solid tumour disease.

Particularly, such compounds are expected to be useful in the prevention or treatment of those tumours which are sensitive to inhibition of one or more of the multiple non-receptor tyrosine kinases such as c-Src kinase that are involved in the signal transduction steps which lead to

the invasiveness and migratory ability of metastasising tumour cells. Further, such compounds are expected to be useful in the prevention or treatment of those tumours which are mediated alone or in part by inhibition of the enzyme c-Src, *i.e.* the compounds may be used to produce a c-Src enzyme inhibitory effect in a warm-blooded animal in need of such treatment. Specifically, such compounds are expected to be useful in the prevention or treatment of solid tumour disease.

Linkage of Growth Factor Receptors to Blood Pressure Effects

A complex interaction of a number of mediators leads to the strict control of blood pressure in the normal mammal. The system is such that if the level of one mediator changes the resultant effect is compensated for by the other mediators such that normal blood pressure is maintained (Guyton *et al.*, Annual Review of Physiology, 1972, 34, 13-46, and Quan *et al.*, Pacing and Clinical Electrophysiology, 1997, 20, 764-774). It is important that blood pressure is tightly controlled because hypertension underlies a variety of cardiovascular diseases such as stroke, acute myocardial infarction and renal failure.

Many substances exhibit effects on blood vessels *in vitro* which, in isolation, would suggest effects on blood pressure *in vivo*. However, because of the nature of the compensation mechanisms that control blood pressure, it is often the case that anticipated *in vivo* effects are not obtained and thus normal blood pressure is maintained. It has been reported that various growth factor receptors may be involved as mediators in the control of blood pressure in the normal mammal.

(a) *Blood Pressure Effects of VEGF Receptor Tyrosine Kinases*

It has been reported that VEGF and FGF have acute effects on vascular tone. VEGF has been shown to dilate dog coronary arteries *in vitro* (Ku *et al.*, Amer. J. Physiology, 1993, 265, H585-H592) and to induce hypotension in the conscious rat (Yang *et al.*, J. Cardiovascular Pharmacology, 1996, 27, 838-844). However, *in vivo* the effects of these agents are only transitory. Even with a very large dose of VEGF (250 µg/kg) in conscious rats, Yang *et al.* observed a return to normal blood pressure within 20 minutes. At lower doses of VEGF, blood pressure returned to normal significantly faster. A similar effect was observed in anaesthetised rats with the blood pressure returning to normal within 30 minutes of the administration of 15 µg/kg bFGF (Boussairi *et al.*, J. Cardiovascular Pharmacology, 1994, 23, 99-102). These studies also showed that tachyphylaxis (or desensitisation) quickly

develops following growth factor administration. Thus, further administration of growth factor has no effect on blood pressure.

It has been reported that the vasodilation induced by both FGF and VEGF depends, at least in part, on the release of nitric oxide (Morbidelli *et al.*, Amer. J. Physiology, 1996, 270, 5 H411-H415 and Wu *et al.*, Amer. J. Physiology, 1996, 271, H1087-H1093).

The complexity and confusion as to the effect of VEGF on blood pressure is illustrated by the following two patent applications that disclose contrasting effects.

A method for treating a hypertensive disorder in a pregnant woman is described in International Patent Application WO 98/28006, the method comprising administering an 10 amount of a therapeutic substance which regulates the amount and/or activity of VEGF. Thus, according to this disclosure, a VEGF RTK inhibitor may be expected to reduce blood pressure.

However, a method for treating essential hypertension is described in International Patent Application WO 00/13703, the method comprising administering to a patient an 15 effective amount of an angiogenic factor such as VEGF, or an agonist thereof. Thus, according to this disclosure, a VEGF RTK inhibitor may be expected to increase blood pressure.

More recently, it has been disclosed in International Patent Application WO 01/74360 that VEGF receptor tyrosine kinase inhibitors, provided that they possess suitable 20 pharmacokinetic properties which provide reasonable bioavailability, do lead to a sustained increase in blood pressure when administered to rats, particularly when administered chronically.

(b) *Blood Pressure Effects of Src Non-Receptor Tyrosine Kinase*

As with the initial studies of the effect of VEGF on blood pressure, there is complexity 25 and confusion as to the effect of Src kinase on blood pressure as illustrated by the following two groups of disclosures.

On the one hand, it has been disclosed in various papers concerning the *in vitro* electrophysiologic effects of tyrosine kinases including c-Src kinase that tyrosine kinase enzymatic activity can be involved in the movement of calcium ions across cellular 30 membranes (Wijetunge *et al.*, Biochem. Biophys. Res. Comm., 1992, 189, 1620-1623, Biochem. Biophys. Res. Comm., 1995, 217, 1039-1044 and British Journal of Pharmacology, 1998, 124, 307-316 and Hu *et al.*, Journal of Biological Chemistry, 1998, 273, 5337-5342).

However, there does not appear to have been any disclosure of the relevance of such *in vitro* effects of Src kinase on blood pressure control *in vivo* in a warm-blooded animal such as man.

In contrast, it has been disclosed in International Patent Application WO 99/61590 that Src kinase may be used to modulate the angiogenesis in tissues caused by 'angiogenic molecules' such as bFGF. As discussed hereinbefore, VEGF is another 'angiogenic molecule'. In addition, it has been disclosed by Cheresh *et al.*, in Nature Medicine, 2001, 7, 222-227, and International Patent Application WO 01/45751, that the angiogenesis factor VEGF is produced in response to ischaemic injury, for example cerebral ischaemia (stroke) in the brain. It was disclosed that VEGF alone did not cause an increase in vascular permeability leading to brain oedema and tissue damage but that Src kinase activity regulates (*i.e.* controls) the ability of VEGF to increase vascular permeability and that a Src kinase inhibitor could block vascular permeability. Using animal studies, it was disclosed that the administration of the Src inhibitor PP1 reduced infarct volume following cerebral ischaemia and that there was no direct effect on cerebral blood flow. It was asserted that Src kinase inhibition may be useful to prevent secondary damage following a stroke and may also 'impact the course of other ischemic diseases such as myocardial infarction'.

If Src kinase activity does control the effectiveness of VEGF, it might be reasonable to expect that a Src kinase inhibitor, when administered chronically, would have a similar effect on blood pressure as a VEGFR tyrosine kinase inhibitor *i.e.* a hypertensive effect (as disclosed in International Patent Application WO 01/74360).

However, more recently, it is described in co-pending United Kingdom Patent Application No. 0307333.5 or No. 0307335.0 that Src kinase inhibitors do cause a decrease in blood pressure. In particular, a selective Src kinase inhibitor causes a substantial decrease in blood pressure. More particularly, a selective Src kinase inhibitor that possesses pharmacokinetic properties which provide a reasonable bioavailability when administered chronically to a warm-blooded animal causes a sustained decrease in blood pressure.

Disclosures of the combination of a VEGF receptor kinase inhibitor and a Src kinase inhibitor

It is disclosed in International Patent Applications WO 97/22596, WO 98/13354 and WO 01/32651 that the anti-angiogenic and/or vascular permeability reducing compounds defined therein may be administered as a sole therapy or in conjunction with surgery, radiotherapy or chemotherapy. The listed chemotherapy options included anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase

plasminogen activator receptor function) and inhibitors of growth factor function (for example platelet derived growth factor and hepatocyte growth factor, growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors).

- Further, it is disclosed in International Patent Applications WO 01/94341 and
- 5 WO 02/16352 that a Src kinase inhibitor may be used to provide an anti-invasive treatment either as a sole therapy or in conjunction with conventional surgery or radiotherapy or chemotherapy. The several classes of chemotherapeutic agents that are listed therein include anti-angiogenic agents such as those which inhibit VEGF such as the compounds disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and
- 10 WO 98/13354 and those that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin).

The present invention

The present invention relates to ways in which an anti-angiogenic and an anti-cancer effect, especially an anti-tumour effect, for example that based in part on the anti-angiogenic 15 effect of a VEGF receptor tyrosine kinase inhibitor, may be produced in a warm-blooded animal such as a human being without causing the hypertension that is associated with the use of an anti-angiogenic agent.

Hypertension is a prevalent cardiovascular disorder that affects many millions of people and, despite the availability of several classes of anti-hypertensive agents, cardiovascular 20 disease remains an important cause of patient morbidity and mortality. Accordingly, it may be useful to counter the sustained increase in blood pressure that occurs when an anti-angiogenic agent such as a VEGF receptor tyrosine kinase inhibitor is administered.

According to the present invention there is provided the use of an anti-angiogenic agent in combination with an inhibitor of the Src family of non-receptor tyrosine kinases 25 (hereinafter a Src kinase inhibitor) in the manufacture of a medicament for use in the treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis characterised in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

30 According to a further feature of the present invention there is provided a method for the treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis which comprises the administration of an effective amount of an

anti-angiogenic agent in combination with an effective amount of a Src kinase inhibitor characterised in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

5 It will be appreciated that disease states that have been associated with angiogenesis include cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, lymphoedema, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, excessive scar formation and adhesions, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation including
10 age-related macular degeneration. Cancer may affect any tissue and includes leukaemia, multiple myeloma and lymphoma. In particular, application of the invention is expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. Further, application of the invention is expected to inhibit any form of cancer associated with VEGF including leukaemia, mulitple myeloma and
15 lymphoma and also, for example, the growth of those primary and recurrent solid tumours which are associated with VEGF, especially those tumours which are significantly dependent on VEGF for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.

According to a further feature of the present invention there is provided the use of an
20 anti-angiogenic agent in combination with a Src kinase inhibitor in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

25 According to a further feature of the present invention there is provided a method for the production of an anti-cancer effect in a warm-blooded mammal such as a human being which comprises the administration of an effective amount of an anti-angiogenic agent in combination with an effective amount of a Src kinase inhibitor characterised in that an appropriate dose of each component of the combination is selected such that the contrasting
30 blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

In particular, the present invention is useful in the treatment of solid tumours *i.e.* it provides an anti-tumour effect.

It is to be understood that the term "in combination with" envisages the simultaneous, separate or sequential administration of the components of the combination. In one aspect of the invention, "in combination with" envisages simultaneous administration of the anti-angiogenic agent and the Src kinase inhibitor. In a further aspect of the invention, "in combination with" envisages sequential administration of those agents. In another aspect of the invention, "in combination with" envisages separate administration of those agents.

Where the administration of those agents is sequential or separate, the delay in administering the second component should not be such as to lose the benefit of the counter-balancing effect on blood pressure that is the aim of the combination therapy of the present invention. Thus,

for the avoidance of doubt, the present invention provides the use of a combination of an anti-angiogenic agent in combination with a Src kinase inhibitor in the manufacture of a medicament that may be administered simultaneously, sequentially or separately to produce an anti-tumour effect in a warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

Cancers that are amenable to treatment with the combination of the present invention include, in particular, oesophageal cancer, myeloma, hepatocellular, pancreatic and cervical cancer, Ewings tumour, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer [including non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)], gastric cancer, head and neck cancer, brain cancer and renal cancer, and haematological cancer such as lymphoma and leukaemia.

The anti-cancer treatment of the present invention may be assessed by conventional means such as the response rate, the time to disease progression and/or the survival rate.

Anti-tumour effects of the present invention include, but are not limited to, inhibition of tumour growth, tumour growth delay, regression of tumour, shrinkage of tumour, increased time to regrowth of tumour on cessation of treatment and slowing of disease progression. For example, it is expected that when the combination of the present invention is administered to a warm-blooded mammal such as a human being who is in need of treatment for solid tumour disease, such a method of treatment will produce an effect on, for example, one or more of the extent of the anti-tumour effect, the response rate, the time to disease progression and the survival rate.

The combination treatment as defined hereinbefore requires that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced. In one embodiment of the present invention, a first component of the 5 combination is dosed at its conventional dose and the second component is dosed in an amount that substantially counter-balances the blood pressure effect associated with the individual use of the first component. Blood pressure effects are measured by conventional means. Thereby the anti-cancer effect is maintained or improved as measured by one or more of the extent of the response, the response rate, the time to disease progression and survival 10 data, in particular the duration of the response. In another embodiment of the present invention, the conventional dose of the first component of the combination may be reduced and the second component is dosed in an amount that substantially counter-balances the blood pressure effect associated with the individual use of the first component and the anti-cancer effect is maintained or improved as measured by one or more of the extent of the response, the 15 response rate, the time to disease progression and survival data, in particular the duration of the response. Thereby the anti-cancer effect is maintained or improved but with fewer and/or less troublesome side-effects than those that may occur if conventional doses of each component are used.

Anti-angiogenic agents that possess pharmacokinetic properties which provide a 20 reasonable bioavailability when administered chronically lead to an increase in diastolic blood pressure in the rat of about 10 to 30 mm Hg and in human beings of about 10 to 20 mm Hg. Src kinase inhibitors that possess pharmacokinetic properties which provide a reasonable bioavailability after a single dose lead to a decrease in diastolic blood pressure in the rat of about 10 to 25 mm Hg. It will be appreciated that the contrasting blood pressure effects 25 associated with the individual use of either of an anti-angiogenic agent or of a Src kinase inhibitor will be substantially counter-balanced if the Src kinase inhibition reduces the hypertensive effect of the anti-angiogenic agent on diastolic blood pressure to less than about 10 mm Hg, particularly to less than about 5 mm Hg. Further, the blood pressure effects will be substantially counter-balanced if the resultant diastolic blood pressure effect of appropriate 30 doses of a combination of the anti-angiogenic agent and the Src kinase inhibitor is in the range of about -10 to +10 mm Hg, particularly in the range of about -5 to +5 mm Hg. More particularly, the blood pressure effects will be substantially counter-balanced if an approximately normotensive effect is achieved.

Subject to that counter-balancing need, an anti-angiogenic agent as defined hereinbefore will generally be administered chronically so that a daily dose in the range, for example, 0.01 mg/kg to 50 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for 5 example, for intravenous administration, a daily dose in the range, for example, 0.01 mg/kg to 25 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a daily dose in the range, for example, 0.01 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form, to provide a daily dose in the range, for example, 0.01 mg/kg to 10 mg/kg body weight, conveniently 0.01 mg/kg to 10 5 mg/kg body weight.

Subject to that counter-balancing need, a Src kinase inhibitor as defined hereinbefore will generally be administered chronically so that a daily dose in the range, for example, 0.02 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for 15 example, for intravenous administration, a daily dose in the range, for example, 0.01 mg/kg to 30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a daily dose in the range, for example, 0.01 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form, to provide a daily dose in the range, for example, 0.02 mg/kg to 15 mg/kg body weight, conveniently 0.02 mg/kg to 20 5 mg/kg body weight.

According to a further feature of the present invention there is provided the use of an anti-angiogenic agent in combination with a Src kinase inhibitor in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded mammal such as a human being characterised in that :-

25 (i) an improved anti-cancer effect is obtained comprising both an anti-angiogenic and an anti-invasive effect; and

(ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

30 According to a further feature of the present invention there is provided a method for the production of an anti-cancer effect in a warm-blooded mammal such as a human being which comprises the administration of an effective amount of an anti-angiogenic agent in combination with an effective amount of a Src kinase inhibitor characterised in that :-

(i) an improved anti-cancer effect is obtained comprising both an anti-angiogenic and an anti-invasive effect; and

(ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component 5 of the combination are substantially counter-balanced.

According to this aspect of the invention, the combination is useful in providing an improved anti-cancer effect comprising both an anti-angiogenic and an anti-invasive effect. According to the present invention, a combination treatment is defined as affording an improved anti-cancer effect if the effect is therapeutically superior to that achievable on 10 dosing one or other of the components of the combination treatment, as measured by, for example, the extent of the response, the response rate, the time to disease progression or the survival period. For example, the effect of the combination treatment is improved if the effect is therapeutically superior to the effect achievable with an anti-angiogenic agent or a Src kinase inhibitor alone. Further, the effect of the combination treatment is improved if a 15 beneficial effect is obtained in a group of patients that does not respond (or responds poorly) to an anti-angiogenic agent or a Src kinase inhibitor alone. Further, the effect of the combination treatment is improved if a beneficial effect is obtained but with fewer and/or less troublesome side-effects than those that may occur if conventional doses of each component are used.

20 According to a further feature of the present invention there is provided the use of an anti-angiogenic agent in combination with a Src kinase inhibitor in the manufacture of a medicament for use in the prevention or treatment of solid tumour disease in a warm-blooded mammal such as a human being characterised in that :-

(i) an improved anti-tumour effect is obtained comprising both an anti-angiogenic 25 and an anti-invasive effect; and

(ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

According to a further feature of the present invention there is provided a method for 30 the prevention or treatment of solid tumour disease in a warm-blooded mammal such as a human being which comprises the administration of an effective amount of an anti-angiogenic agent in combination with an effective amount of a Src kinase inhibitor characterised in that :-

- (i) an improved anti-tumour effect is obtained comprising both an anti-angiogenic and an anti-invasive effect; and
- (ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component 5 of the combination are substantially counter-balanced.

According to a further feature of the present invention there is provided the use of an inhibitor of VEGF receptor tyrosine kinases in combination with a Src kinase inhibitor in the manufacture of a medicament for use in the prevention or treatment of solid tumour disease in a warm-blooded mammal such as a human being characterised in that :-

- 10 (i) an improved anti-tumour effect is obtained comprising both an anti-angiogenic and an anti-invasive effect; and

(ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

- 15 According to a further feature of the present invention there is provided a method for the prevention or treatment of solid tumour disease in a warm-blooded mammal such as a human being which comprises the administration of an effective amount of an inhibitor of VEGF receptor tyrosine kinases in combination with an effective amount of a Src kinase inhibitor characterised in that :-

- 20 (i) an improved anti-tumour effect is obtained comprising both an anti-angiogenic and an anti-invasive effect; and

(ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

- 25 According to a further feature of the present invention there is provided the use of an inhibitor of VEGF receptor tyrosine kinases in a combination with a Src kinase inhibitor in the manufacture of a medicament for use in a warm-blooded mammal such as a human being in the prevention or treatment of those tumours which are sensitive to inhibition of one or both of VEGF receptor tyrosine kinase and Src kinase characterised in that an appropriate dose of 30 each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

According to a further feature of the present invention there is provided a method for the prevention or treatment of those tumours which are sensitive to inhibition of one or both of VEGF receptor tyrosine kinase and Src kinase which comprises the administration to a warm-blooded mammal such as a human being of an effective amount of an inhibitor of
5 VEGF receptor tyrosine kinases in combination with an effective amount of a Src kinase inhibitor characterised in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

A suitable anti-angiogenic agent is any agent which inhibits the growth and maintenance
10 of new blood vessels by inhibiting VEGF signalling. Suitable anti-angiogenic agents include :-
(i) inhibitors of one or more VEGF receptor tyrosine kinases;
(ii) VEGF antibodies such as bevacizumab (AvastinTM, Genentech) and VEGF receptor antibodies such as IMC-1C11 (ImClone Systems); and
15 (iii) inhibitors of VEGF expression such as RPI 4610 (AngiozymeTM, Chiron Corporation/Ribozyme Pharmaceuticals).

A suitable anti-angiogenic agent is also any agent which inhibits the growth and maintenance of new blood vessels by vascular targeting. Suitable vascular targeting agents include Combretastatin A4 phosphate (Oxigene, Bristol Myers Squibb, US Patent No. 4,996,237); AVE-8062; ExherinTM (Adherex); 5,6-dimethylxanthenone-4-acetic acid (DMXAA); and vascular damaging agents described in International Patent Applications WO 99/02166 and WO 00/40529. A preferred vascular damaging agent is N-acetylcolchinol-O-phosphate (Example 1 of International Patent Application WO 99/02166) which is also known as ZD6126 (AstraZeneca).

Conveniently, the anti-angiogenic agent is an inhibitor of one or more VEGF receptor
25 tyrosine kinases. Such compounds include ZD6474 (AstraZeneca, Example 2 of International Patent Application WO 01/32651), vatalanibTM (PTK787/ZK 222584; Novartis/Schering, International Patent Application WO 98/35958), SU11248 (Pharmacia; International Patent Application WO 01/60814), CP-547632 (Pfizer; International Patent Application WO 99/62890) and CEP-7055 (Cephalon).

30 A suitable anti-angiogenic agent is an inhibitor of the VEGF receptor tyrosine kinase enzymes that, in general, possesses one or more of :-
(i) IC₅₀ values against Flt-1 and/or KDR in the range, for example, 0.001 to 5μM, preferably in the range, for example, 0.001 to 0.5μM;

(ii) greater inhibitory potency against VEGF receptor kinases than against Src kinase; and

(iii) pharmacokinetic properties which provide a reasonable bioavailability when administered to a warm-blooded animal, especially when administered chronically.

5 The activity of a compound against VEGF receptor tyrosine kinases such as Flt-1 and KDR may also be assessed using appropriate conventional assays such as those described in, for example, International Patent Application WO 98/13354.

Compounds which are inhibitors of VEGF receptor tyrosine kinases are described in, for example, International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856, 10 WO 97/34876, WO 97/42187, WO 98/13354, WO 98/13350, WO 99/10349, WO 00/21955, WO 00/47212, WO 01/32651, WO 01/66099, WO 01/77085, WO 02/12226, WO 02/12227, WO 02/12228 and WO 02/16348 and in co-pending International Patent Application No. PCT/GB/03/00343.

Selective inhibitors of the VEGF receptor tyrosine kinase enzymes possess greater 15 inhibitory potency against VEGF receptor kinases than against other tyrosine kinase enzymes.

Suitable selective VEGF receptor tyrosine kinase inhibitors for use in the present invention possess potent inhibitory activity against VEGF receptor tyrosine kinases such as Flt-1 and KDR that have been shown to bind VEGF with high affinity whilst possessing less potent inhibitory activity against other tyrosine kinase enzymes such as other receptor tyrosine 20 kinases or against non-receptor tyrosine kinases, in particular against the Src family of non-receptor tyrosine kinases, for example c-Src and/or c-Yes. Given the above-mentioned anti-hypertensive effect of Src kinase inhibition, it will be appreciated that compounds exhibiting such VEGF receptor selectivity provide a greater degree of hypertension than those which possess significant Src kinase inhibitory activity.

25 In general, a VEGF receptor tyrosine kinase inhibitor for use in the present invention possesses a KDR IC₅₀ in the range, for example, 0.001 - 1 μM and a Src kinase IC₅₀ in the range, for example, 0.01 - 100 μM. The selectivity of the VEGF receptor tyrosine kinase inhibition of a test compound may be assessed by dividing the Src kinase IC₅₀ by the KDR IC₅₀ to provide a ratio. A compound possesses substantially better potency against VEGF receptor 30 tyrosine kinases than against Src kinase when the ratio of Src kinase IC₅₀ to KDR IC₅₀ is :-

- (i) in general, in the range, for example, of about 2 to 1,000;
- (ii) particularly, in the range, for example, of about 10 to 1,000; and
- (iii) preferably, in the range, for example, of about 50 to 1,000.

Suitable compounds which possess such selective VEGF receptor tyrosine kinase inhibitory properties are described in, for example, International Patent Applications WO 97/22596, WO 97/30035, WO 98/13354, WO 00/47212, WO 01/32651 and WO 01/77085, and in co-pending International Patent Application No. PCT/GB/03/00343.

5 Particular selective VEGF receptor tyrosine kinase inhibitors are described in, for example, International Patent Applications WO 00/47212 and WO 01/32651 and in co-pending International Patent Application No. PCT/GB/03/00343.

In general, a suitable compound that is a Src kinase inhibitor is a compound that possesses one or more of :-

10 (i) an IC₅₀ value in the range, for example, 0.001 to 5μM, preferably in the range, for example, 0.001 to 0.5μM;

(ii) greater inhibitory potency against Src kinase than against VEGF receptor kinases; and

15 (iii) pharmacokinetic properties which provide a reasonable bioavailability when administered to a warm-blooded animal, especially when administered chronically.

The potency of a compound as a Src kinase inhibitor may be assessed using a conventional Elisa assay such as that described in, for example, International Patent Application WO 01/94341.

Compounds which possess Src kinase inhibitory properties are described in, for 20 example, International Patent Applications WO 01/94341, WO 02/16352, WO 02/30924, WO 02/30926, WO 02/34744, WO 02/085895, WO 02/092577, WO 02/092578, WO 02/092579 and WO 03/008409 and in co-pending European Patent Application No. 02292736.2.

It is disclosed in Journal Medicinal Chemistry, 2001, 44, 822-833 and 3965-3977 that 25 certain 4-anilino-3-cyanoquinoline derivatives are useful for the inhibition of Src-dependent cell proliferation. The 4-anilino-3-cyanoquinoline Src inhibitor known as SKI 606 is described in Cancer Research, 2003, 63, 375.

Other compounds which possess Src kinase inhibitory properties are described in, for example, International Patent Applications WO 96/10028, WO 97/07131, WO 97/08193, 30 WO 97/16452, WO 97/28161, WO 97/32879 and WO 97/49706.

Other compounds which possess Src kinase inhibitory properties are described in, for example, International Patent Application WO 03/013540 [particularly the compounds disclosed therein by way of Formulae I to VIII and compounds of Formulae VII and VIII

wherein the 2,6-dimethylphenyl group is replaced by a 2,6-dichlorophenyl or a 2-chloro-6-methylphenyl group].

Other compounds which possess Src kinase inhibitory properties are described in, for example, J Bone Mineral Research, 1999, 14 (Suppl. 1), S487, Molecular Cell, 1999, 3, 639-5 647, Journal Medicinal Chemistry, 1997, 40, 2296-2303, Journal Medicinal Chemistry, 1998, 41, 3276-3292 and Bioorganic & Medicinal Chemistry Letters, 2002, 12, 1361 and 3153.

Particular Src kinase inhibitors include :-

- (i) 4-amino-5-(3-methoxyphenyl)-7-{4-[2-(2-methoxyethylamino)ethoxy]phenyl}-pyrrolo[2,3-*d*]pyrimidine and 4-amino-5-(3-methoxyphenyl)-10 7-(4-{2-[di-(2-methoxyethyl)amino]ethoxy}phenyl)pyrrolo[2,3-*d*]pyrimidine which are obtainable by methods described in International Patent Application WO 96/10028;
 - (ii) 4-amino-7-*tert*-butyl-5-(4-tolyl)pyrazolo[3,4-*d*]pyrimidine which is also known as PP1 and is described in Molecular Cell, 1999, 3, 639-648;
 - (iii) 2-(2,6-dichloroanilino)-6,7-dimethyl-1,8-dihydroimidazo[4,5-*h*]isoquinolin-9-one and 15 2-(2,6-dichloroanilino)-7-[(E)-3-diethylaminoprop-1-enyl]-6-methyl-1,8-dihydroimidazo[4,5-*h*]isoquinolin-9-one which are obtainable by methods described in Journal Medicinal Chemistry, 2002, 45, 3394;
 - (iv) 1-[6-(2,6-dichlorophenyl)-2-(4-diethylaminobutyl)pyrido[2,3-*d*]pyrimidin-7-yl]-3-ethylurea which is obtainable by methods described in Journal Medicinal Chemistry, 1997, 20 40, 2296-2303 and Journal Medicinal Chemistry, 2001, 44, 1915;
 - (v) 6-(2,6-dichlorophenyl)-2-[4-(2-diethylaminoethoxy)anilino]-8-methyl-8*H*-pyrido[2,3-*d*]pyrimidin-7-one which is also known as PD166285 and is described in J. Pharmacol. Exp. Ther., 1997, 283, 1433-1444;
 - (vi) the compound known as PD162531 which is described in Mol. Biol. Cell, 2000, 11, 25 51-64;
 - (vii) the compound known as PD166326 which is described in Biochem. Pharmacol., 2000, 60, 885-898; and
 - (viii) the compound known as PD173955 which is described in Cancer Research, 1999, 59, 6145-6152.
- 30 Other compounds which may possess Src kinase inhibitory properties are described in, for example, International Patent Applications WO 02/079192, WO 03/000188, WO 03/000266, WO 03/000705, WO 02/083668, WO 02/092573, WO 03/004492, WO 00/49018, WO 03/013541, WO 01/00207, WO 01/00213 and WO 01/00214.

Selective Src kinase inhibitors possess greater inhibitory potency against Src kinase than against VEGF receptor kinases. Suitable selective Src kinase inhibitors for use in the present invention possess potent inhibitory activity against the Src family of non-receptor tyrosine kinases, for example by inhibition of c-Src and/or c-Yes, whilst possessing less potent inhibitory activity against other tyrosine kinase enzymes such as the receptor tyrosine kinases, in particular against VEGF receptor tyrosine kinases such as Flt-1 and KDR that have been shown to bind VEGF with high affinity. Compounds exhibiting such Src selectivity provide a greater degree of hypotension than those which possess significant VEGF receptor tyrosine kinase inhibitory activity.

In general, a Src kinase inhibitor for use in the present invention possesses a Src kinase IC₅₀ in the range, for example, 0.001 - 1 μM and a KDR IC₅₀ in the range, for example, 0.1 - 100 μM. The selectivity of the Src kinase activity of a test compound may be assessed by dividing the KDR IC₅₀ by the Src kinase IC₅₀ to provide a ratio. When it is stated that the Src kinase inhibitor possesses substantially better potency against Src kinase than against VEGF receptor tyrosine kinases, this means that the ratio of KDR IC₅₀ to Src kinase IC₅₀ is :-

- (i) in general, in the range, for example, of about 5 to 10,000;
- (ii) particularly, in the range, for example, of about 25 to 10,000; and
- (iii) preferably, in the range, for example, of about 100 to 10,000.

Suitable compounds which possess such selective Src kinase inhibitory properties are described in, for example, International Patent Applications WO 01/94341, WO 02/16352, WO 02/30924, WO 02/30926, WO 02/34744, WO 02/085895, WO 02/092577, WO 02/092578, WO 02/092579 and WO 03/008409 and in co-pending European Patent Application No. 02292736.2.

Particular selective Src kinase inhibitors are described in, for example, International Patent Applications WO 01/94341, WO 02/16352, WO 02/085895, WO 02/092577, WO 02/092578 and WO 02/092579 and in co-pending European Patent Application No. 02292736.2.

Further particular inhibitors of VEGF receptor tyrosine kinases and Src kinase inhibitors that may be used in the present invention include those compounds that possess appropriate pharmacokinetic properties after administration to a warm-blooded mammal such as a rat, dog or human being, particularly after oral administration. Such compounds provide suitable blood levels and a reasonable bioavailability when administered acutely, particularly when administered chronically. In general, the VEGF receptor tyrosine kinase inhibitor and

the Src kinase inhibitor as defined hereinbefore will be administered chronically over a number of days to allow assessment of the anti-cancer effect of the combination, particularly of the effect on solid tumour disease, and of any effect on the patient's blood pressure. In general, oral administration is preferred, particularly using tablet forms.

5 In general, each of an inhibitor of VEGF receptor tyrosine kinases and a Src kinase inhibitor that possesses suitable pharmacokinetic properties when administered to a warm-blooded mammal such as a human being possesses one or more of the following pharmacokinetic parameters :-

- 10 (i) Compound Clearance of less than about 75% of hepatic blood flow (hepatic blood flow in the human is about 25 ml/min/kg, in the dog is about 35 ml/min/kg and in the rat is about 75 ml/min/kg);
(ii) a Volume of Distribution of less than about 30 L/kg;
(iii) a bioavailability of more than about 20%; and
(iv) an elimination half life in the range, for example, of about 0.2 to 15 hours.

15 In general, each of a particular VEGF receptor tyrosine kinase inhibitor and a particular Src kinase inhibitor that possesses suitable pharmacokinetic properties when administered to a warm-blooded mammal such as a human being possesses one or more of the following pharmacokinetic parameters :-

- 20 (i) Compound Clearance of less than about 50% of hepatic blood flow;
(ii) a Volume of Distribution of less than about 20 L/kg;
(iii) a bioavailability of more than about 30%; and
(iv) an elimination half life in the range, for example, of about 0.5 to 10 hours.

In general, each of a more particular VEGF receptor tyrosine kinase inhibitor and a more particular Src kinase inhibitor that possesses suitable pharmacokinetic properties when 25 administered to a warm-blooded mammal such as a human being possesses one or more of the following pharmacokinetic parameters :-

- 30 (i) Compound Clearance of less than about 40% of hepatic blood flow;
(ii) a Volume of Distribution of less than about 10 L/kg;
(iii) a bioavailability of more than about 40%; and
(iv) an elimination half life in the range, for example, of about 1 to 7.5 hours.

Particular selective VEGF receptor tyrosine kinase inhibitors that may be used for chronic administration in the present invention are described in, for example, International

Patent Applications WO 00/47212 and WO 01/32651 and in co-pending International Patent Application No. PCT/GB/03/00343.

Particular VEGF receptor tyrosine kinase inhibitors include the following compounds from International Patent Application No. WO 00/47212 :-

- 5 6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
4-(6-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
10 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-
4-yl)methoxy)quinazoline,
15 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-
1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
(2R)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-
6-methoxyquinazoline, and
20 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-
4-yl)ethoxy)quinazoline;
and pharmaceutically-acceptable salts thereof.

Further particular VEGF receptor tyrosine kinase inhibitors include the following compounds from International Patent Application No. WO 01/32651 :-

- 25 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
30 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline, and

4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline; and pharmaceutically-acceptable salts thereof.

- Further particular VEGF receptor tyrosine kinase inhibitors include the following compounds from co-pending International Patent Application No. PCT/GB/03/00343 :-
- 5 6-(3-(4-acetylpirperazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-7-methoxyquinazoline,
 - 7-(3-(4-acetylpirperazin-1-yl)propoxy)-4-(7-azaindol-5-yloxy)-6-methoxyquinazoline,
 - 4-(7-azaindol-5-yloxy)-6-methoxy-7-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)quinazoline,
 - 10 4-(7-azaindol-5-yloxy)-6-methoxy-7-[2-(N-methyl-N-prop-2-yn-1-ylamino)ethoxy]quinazoline,
 - 4-(4-fluoro-2-methylindol-5-yloxy)-7-methoxy-6-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)quinazoline,
 - 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)quinazoline,
 - 15 6-(3-(4-acetylpirperazin-1-yl)propoxy)-4-(4-fluoroindol-5-yloxy)-7-methoxyquinazoline,
 - 7-[(1-acetylpirperidin-4-yl)methoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline,
 - 7-[(2S)-1-acetylpyrrolidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-
 - 20 6-methoxyquinazoline,
 - 7-[(2R)-1-acetylpyrrolidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline,
 - 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[1-(2,2,2-trifluoroethyl)piperidin-4-ylmethoxy]quinazoline,
 - 25 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy}quinazoline,
 - 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethoxy}quinazoline,
 - 7-{2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-
 - 30 6-methoxyquinazoline,
 - 7-{2-[2-(4-acetylpirperazin-1-yl)ethoxy]ethoxy}-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline,

- 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-[(1-isobutyrylpiperidin-4-yl)methoxy]-6-methoxyquinazoline,
- 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-{[(2*R*)-1-isobutyrylpyrrolidin-2-yl]methoxy}-6-methoxyquinazoline,
- 5 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{{[1-(methylsulfonyl)piperidin-4-yl]methoxy}quinazoline,
- 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{{[(2*S*)-1-(methylsulfonyl)pyrrolidin-2-yl]methoxy}quinazoline,
- 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{{[(2*R*)-1-(methylsulfonyl)pyrrolidin-2-yl]methoxy}quinazoline,
- 10 7-[3-(4-allylpiperazin-1-yl)propoxy]-4-(7-azaindol-5-yloxy)-6-methoxyquinazoline,
- 4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]propoxy}quinazoline,
- 7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
- 15 6-methoxyquinazoline,
- 7-[3-(4-acetyl)piperazin-1-yl)propoxy]-4-(1*H*-indol-5-yloxy)-6-methoxyquinazoline,
- 7-[(2*S*)-1-carbamoylpiperidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
- 7-{3-[4-carbamoylpiperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
- 20 6-methoxyquinazoline,
- 7-{3-[2,5-dioxo-4-(1-hydroxy-1-methylethyl)imidazolidin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yloxy]-6-methoxyquinazoline,
- 6-[(1-acetyl)piperidin-4-yl)oxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxyquinazoline,
- 4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxy-6-{{[1-(methylsulphonyl)piperidin-4-yl]oxy}quinazoline,
- 25 7-[3-(4-acetyl)piperazin-1-yl)propoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{2-[*N*-methyl-*N*-(2-propynyl)amino]ethoxy}quinazoline,
- 7-[3-(4-acetyl)piperazin-1-yl)propoxy]-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline,
- 30 7-[3-(4-acetyl)piperazin-1-yl)propoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
- 7-[3-(4-carbamoylmethyl)piperazin-1-yl)propoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

- 7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline,
 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-{(2*R*)-2-hydroxy-3-[4-prop-2-yn-1-yl]piperazin-1-yl}propoxy}-6-methoxyquinazoline,
 5 7-{(2*R*)-3-[(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)]-2-hydroxypropoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
 7-{(2*R*)-3-[4-acetylpiperazin-1-yl]-2-hydroxypropoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
 7-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-
 10 6-methoxyquinazoline, and
 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
 6-methoxyquinazoline,
 and pharmaceutically-acceptable salts thereof.

More particular selective VEGF receptor tyrosine kinase inhibitors include :-

- 15 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
 20 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline,
 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
 25 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
 4-(2-fluoro-4-methylanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
 30 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
 4-(2-fluoro-4-methylanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,

- 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)quinazoline,
- 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy}quinazoline,
- 5 7-{2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
- 4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]propoxy}quinazoline,
- 7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
- 10 6-methoxyquinazoline,
- 7-[3-(4-acetylpirazin-1-yl)propoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
- 7-(3-(4-acetylpirazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline, and
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
- 15 6-methoxyquinazoline,
- or pharmaceutically-acceptable acid-addition salts thereof.

Preferred selective VEGF receptor tyrosine kinase inhibitors include :-

- 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
- 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
- 20 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline,
- 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
- 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
- 25 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
- 30 4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy}quinazoline,
- 7-{2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

- 4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]propoxy}quinazoline,
7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
6-methoxyquinazoline,
5 7-(3-(4-acetylpirazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-
6-methoxyquinazoline, and
7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
6-methoxyquinazoline;
or a pharmaceutically-acceptable acid-addition salt thereof.

10 A particular preferred VEGF receptor tyrosine kinase inhibitor for use in the invention
is 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline, or
a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the
invention is 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-
15 7-(3-piperidinopropoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt
thereof.

A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the
invention is 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-
1-yl)propoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

20 A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the
invention is 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-
4-yl)ethoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the
invention is 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-
25 4-ylmethoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the
invention is 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-
4-ylmethoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the
30 invention is 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline, or
a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the invention is 4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]propoxy}quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the invention is 7-(3-(4-acetylpirerazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred VEGF receptor tyrosine kinase inhibitor for use in the invention is 7-[2-(4-acetylpirerazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

10 Particular selective Src kinase inhibitors that may be used for chronic administration in the present invention are described in, for example, International Patent Applications WO 01/94341, WO 02/16352, WO 02/085895, WO 02/092577, WO 02/092578 and WO 02/092579 and in co-pending European Patent Application No. 02292736.2.

Particular Src kinase inhibitors include the following compounds from International
15 Patent Application WO 01/94341 :-

- 4-(2-chloro-5-methoxyanilino)-5,7-di-(3-morpholinopropoxy)quinazoline,
4-(2-bromo-5-methoxyanilino)-7-methoxy-5-(N-methylpireridin-4-yloxy)quinazoline,
4-(2-chloro-5-methoxyanilino)-7-methoxy-5-(N-methylpireridin-4-yloxy)quinazoline,
4-(2-chloro-5-methoxyanilino)-7-[3-(4-methylpirerazin-1-yl)propoxy]-5-tetrahydropyran-
20 4-yloxyquinazoline,
4-(2-chloro-5-methoxyanilino)-7-(3-morpholinopropoxy)-5-tetrahydropyran-
4-yloxyquinazoline,
4-(2-chloro-5-methoxyanilino)-7-[2-hydroxy-3-(4-methylpirerazin-1-yl)propoxy]-
5-tetrahydropyran-4-yloxyquinazoline,
25 4-(2-chloro-5-methoxyanilino)-7-(2-hydroxy-3-morpholinopropoxy)-5-tetrahydropyran-
4-yloxyquinazoline,
4-(2-chloro-5-methoxyanilino)-7-[3-(4-methylpirerazin-1-yl)propoxy]-5-tetrahydrofuran-
3-yloxyquinazoline,
4-(2-chloro-5-methoxyanilino)-7-(3-morpholinopropoxy)-5-tetrahydrofuran-
30 3-yloxyquinazoline,
4-(5-chloronaphth-1-ylamino)-7-methoxy-5-(N-methylpireridin-4-yloxy)quinazoline,
4-(3-chlorobenzofuran-7-ylamino)-7-methoxy-5-(N-methylpireridin-4-yloxy)quinazoline,
7-benzyloxy-4-(2-bromo-5-methoxyanilino)-5-piperidin-4-yloxyquinazoline,

- 4-(2-bromo-5-methoxyanilino)-7-(3-methylsulphonylpropoxy)-5-piperidin-4-yloxyquinazoline,
- 4-(2-bromo-5-methoxyanilino)-7-methoxy-5-piperidin-4-ylmethoxyquinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,
- 5 4-(2,5-dimethoxyanilino)-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 10 4-(2,4-dichloro-5-methoxyanilino)-7-(2-morpholinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(2-bromo-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 15 4-yloxyquinazoline,
- 4-(2-bromo-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(2-bromo-5-methoxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(2-bromo-5-methoxyanilino)-7-(4-pyridyloxyethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 20 4-(2-bromo-5-methoxyanilino)-7-{2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(2-bromo-5-methoxyanilino)-7-{2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,
- 25 5-tetrahydropyran-4-yloxyquinazoline,
- 4-(2-bromo-5-methoxyanilino)-7-(4-pyridylmethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(5-methoxy-2-pyrrolidin-1-ylanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 30 4-(2-bromo-5-methoxyanilino)-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-5-cyclopentyloxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-5-piperidin-4-yloxyquinazoline,

- 4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-piperidin-4-yloxyquinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-(N-methylpiperidin-
4-yloxy)quinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxy-5-piperidin-4-ylmethoxyquinazoline,
5 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-yethoxy)-5-tetrahydropyran-
4-yloxyquinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-
4-yloxyquinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-
10 5-tetrahydropyran-4-yloxyquinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-
5-tetrahydropyran-4-yloxyquinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-
4-yloxyquinazoline,
15 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-pyridyloxy)ethoxy]-5-tetrahydropyran-
4-yloxyquinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-piperidin-4-ylmethoxy-5-tetrahydropyran-
4-yloxyquinazoline and
4-(6-chloro-2,3-methylenedioxyanilino)-7-(N-methylpiperidin-4-ylmethoxy)-
20 5-tetrahydropyran-4-yloxyquinazoline;
or a pharmaceutically-acceptable acid-addition salt thereof.

Further particular Src kinase inhibitors include the following compounds from International Patent Application WO 02/16352 :-

- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline,
25 6-methoxy-4-(2,3-methylenedioxyanilino)-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazoline,
6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,
6-methoxy-4-(2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline,
6-methoxy-4-(2,3-methylenedioxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline,
30 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)quinazoline,
6-methoxy-4-(2,3-methylenedioxyanilino)-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
7-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2,3-methylenedioxyanilino)-
quinazoline,

- 7-[2-hydroxy-3-(N-isopropyl-N-methylamino)propoxy]-6-methoxy-
4-(2,3-methylenedioxyanilino)quinazoline;
7-[3-(4-cyanomethylpiperazin-1-yl)-2-hydroxypropoxy]-6-methoxy-
4-(2,3-methylenedioxyanilino)quinazoline,
5 6-methoxy-4-(2,3-methylenedioxyanilino)-7-{2-[2-(4-methylpiperazin-1-
yl)ethoxy]ethoxy}quinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-cyanomethylpiperazin-1-yl)propoxy]-
6-methoxyquinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,
10 4-(6-chloro-2,3-methylenedioxyanilino)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(6-bromo-2,3-methylenedioxyanilino)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
6-methoxy-4-(2,3-methylenedioxyanilino)-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline,
6-methoxy-4-(2,3-methylenedioxyanilino)-7-[2-(4-pyridyloxy)ethoxy]quinazoline,
6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-pyridylmethoxy)quinazoline,
15 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-cyanopyrid-4-ylmethoxy)-
6-methoxyquinazoline and
4-(6-chloro-2,3-methylenedioxyanilino)-6-methoxy-7-(N-methylpiperidin-
4-ylmethoxy)quinazoline;
or a pharmaceutically-acceptable acid-addition salt thereof.

20 Further particular Src kinase inhibitors include the following compounds from

International Patent Application WO 02/085895 :-

- 6-methoxy-4-(2,3-methylenedioxypheoxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,
4-(6-chloro-2,3-methylenedioxypheoxy)-6-methoxy-7-(3-pyrrolidin-
1-ylpropoxy)quinazoline,
25 4-(6-bromo-2,3-methylenedioxypheoxy)-6-methoxy-7-(3-pyrrolidin-
1-ylpropoxy)quinazoline,
6-methoxy-4-(2,3-methylenedioxypheoxy)-7-(3-morpholinopropoxy)quinazoline,
4-(6-chloro-2,3-methylenedioxypheoxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
4-(6-bromo-2,3-methylenedioxypheoxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
30 6-methoxy-4-(2,3-methylenedioxypheoxy)-7-[3-(4-methylpiperazin-
1-yl)propoxy]quinazoline,
4-(6-chloro-2,3-methylenedioxypheoxy)-6-methoxy-7-[3-(4-methylpiperazin-
1-yl)propoxy]quinazoline,

- 4-(6-bromo-2,3-methylenedioxophenoxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline,
6-methoxy-4-(2,3-methylenedioxophenoxy)-7-(3-methylsulphonylpropoxy)quinazoline,
4-(6-chloro-2,3-methylenedioxophenoxy)-6-methoxy-
5 7-(3-methylsulphonylpropoxy)quinazoline and
4-(6-bromo-2,3-methylenedioxophenoxy)-6-methoxy-
7-(3-methylsulphonylpropoxy)quinazoline;
or a pharmaceutically-acceptable acid-addition salt thereof.

Further particular Src kinase inhibitors include the following compounds from

- 10 International Patent Application WO 02/092577 :-

4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
4-(2-chloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline and
4-(2-bromo-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline;
or a pharmaceutically-acceptable acid-addition salt thereof.

- 15 Further particular Src kinase inhibitors include the following compounds from
International Patent Application WO 02/092578 :-

4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,
20 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline and
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(2-piperidin-4-ylethoxy)quinazoline;
or a pharmaceutically-acceptable acid-addition salt thereof.

- Further particular Src kinase inhibitors include the following compounds from
- 25 International Patent Application WO 02/092579 :-
- 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline,
4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline and
4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(2-morpholinoethoxy)quinazoline and
4-(2-bromo-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline
30 or a pharmaceutically-acceptable acid-addition salt thereof.

Further particular Src kinase inhibitors include the following compounds from
co-pending European Patent Application No. 02292736.2 :-

- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]-6-methoxyquinazoline,
- 5 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy}quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxy-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]quinazoline,
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
- 10 5-tetrahydropyran-4-yloxyquinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxyquinazoline and
- 15 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy}-5-isopropoxyquinazoline;
- or a pharmaceutically-acceptable acid-addition salt thereof.
- More particular selective Src kinase inhibitors include the following compounds :-
- 4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-
- 20 4-yloxyquinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-7-(2-morpholinoethoxy)-5-tetrahydropyran-
- 4-yloxyquinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-7-[2-(4-methylpirazin-1-yl)ethoxy]-5-tetrahydropyran-
- 4-yloxyquinazoline,
- 25 4-(2-bromo-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-
- 4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-
- 4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-
- 30 4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-methylpirazin-1-yl)propoxy]-
- 5-tetrahydropyran-4-yloxyquinazoline,

- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 5 7-[2-(4-acetyl

6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-4-(2,3-methylenedioxyanilino)-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazoline,

10 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,

6-methoxy-4-(2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline,

6-methoxy-4-(2,3-methylenedioxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline,

6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)quinazoline,

4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]-

15 6-methoxyquinazoline,

4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,

4-(2-chloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,

4-(2-bromo-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline,

4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-

20 4-ylmethoxy)quinazoline,

4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,

4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline,

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline,

25 7-[2-(4-acetyl

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline},

30 7-[2-(4-acetyl

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-isopropoxyquinazoline};

or a pharmaceutically-acceptable acid-addition salt thereof.

Preferred selective Src kinase inhibitors include the following compounds :-

- 4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 5 4-(2,4-dichloro-5-methoxyanilino)-7-(2-morpholinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 10 4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 15 7-[2-(4-acetylpirerazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline,
- 20 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)quinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]-6-methoxyquinazoline,
- 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,
- 25 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,
- 7-[2-(4-acetylpirerazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline,
- 30 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline},
- 7-[2-(4-acetylpirerazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxyquinazoline and

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-

7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-isopropoxyquinazoline; or a pharmaceutically-acceptable acid-addition salt thereof.

A particular preferred Src kinase inhibitor for use in the invention is

5 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred Src kinase inhibitor for use in the invention is

4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

10 A further particular preferred Src kinase inhibitor for use in the invention is
4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-
5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt
thereof.

A further particular preferred Src kinase inhibitor for use in the invention is

15 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred Src kinase inhibitor for use in the invention is
7-[2-(4-acetyl piperazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-
5-isopropoxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

20 A further particular preferred Src kinase inhibitor for use in the invention is
6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline, or a
pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred Src kinase inhibitor for use in the invention is
6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)quinazoline, or a
25 pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred Src kinase inhibitor for use in the invention is
4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]-
6-methoxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred Src kinase inhibitor for use in the invention is
30 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline, or
a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred Src kinase inhibitor for use in the invention is
7-[2-(4-acetyl piperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-

5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred Src kinase inhibitor for use in the invention is
4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-
5 3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, or a
pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred Src kinase inhibitor for use in the invention is
7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
5-isopropoxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

10 A further particular preferred Src kinase inhibitor for use in the invention is
4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-isopropoxyquinazoline, or a
pharmaceutically-acceptable acid-addition salt thereof.

A suitable pharmaceutically-acceptable salt of those VEGF receptor tyrosine kinase
15 inhibitors as defined hereinbefore or those Src kinase inhibitors as defined hereinbefore that
are sufficiently basic is, for example, a pharmaceutically-acceptable acid-addition salt, for
example an acid-addition salt with an inorganic or organic acid such as hydrochloric,
hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid. A suitable pharmaceutically-
acceptable salt of those VEGF receptor tyrosine kinase inhibitors as defined hereinbefore or
20 those Src kinase inhibitors as defined hereinbefore that are sufficiently acidic is, for example,
a pharmaceutically-acceptable alkali or alkaline earth metal salt such as a calcium or
magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine,
dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

In order to use a VEGF receptor tyrosine kinase inhibitor as defined hereinbefore or a
25 Src kinase inhibitor as defined hereinbefore according to the present invention, the
compounds may be administered using suitable pharmaceutical compositions. For example, a
composition may be in a form suitable for oral administration, for example as a tablet or
capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular,
intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical
30 administration for example as an ointment or cream, for rectal administration for example as a
suppository or the route of administration may be by direct injection into the tumour or by
regional delivery or by local delivery. In other embodiments of the present invention the
components may be delivered endoscopically, intratracheally, intralesionally, percutaneously,

intravenously, subcutaneously or intraperitoneally. In general the compositions described herein may be prepared in a conventional manner using conventional excipients or carriers that are well known in the art.

Suitable pharmaceutically-acceptable excipients or carriers for a tablet formulation 5 include, for example, inert excipients such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or alginic acid, binding agents such as gelatin or starch, lubricating agents such as magnesium stearate, stearic acid or talc, preservative agents such as ethyl or propyl 4-hydroxybenzoate, and anti-oxidants such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their 10 disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract or to improve their stability and/or appearance, in either case using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid excipient, for example, calcium carbonate, 15 calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

Suitable compositions may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative 20 agents.

As stated hereinbefore, it is to be understood that the term a "combination" envisages the simultaneous, separate or sequential administration of the components of the combination. It will be appreciated that the pharmaceutical composition according to the present invention includes a pharmaceutical composition comprising an anti-angiogenic agent and a Src kinase 25 inhibitor as defined hereinbefore and a pharmaceutically-acceptable excipient or carrier. Such a composition conveniently provides the components of the combination for simultaneous administration. A pharmaceutical composition according to the present invention also includes separate compositions comprising a first composition comprising an anti-angiogenic agent and a pharmaceutically-acceptable excipient or carrier, and a second composition 30 comprising a Src kinase inhibitor and a pharmaceutically-acceptable excipient or carrier.

Such a composition conveniently provides the components of the combination for sequential or separate administration but the separate compositions may also be administered simultaneously. Conveniently such a pharmaceutical composition of the invention comprises

a kit comprising a first container with a suitable composition containing the anti-angiogenic agent and a second container with a suitable composition containing the Src kinase inhibitor.

According to this aspect of the present invention there is provided a kit for use in dosing the combination defined hereinbefore comprising :-

- 5 a) an anti-angiogenic agent together with a pharmaceutically-acceptable excipient or carrier, in a first unit dosage form;
- b) a Src kinase inhibitor together with a pharmaceutically-acceptable excipient or carrier, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms; and characterised
- 10 in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

According to a further aspect of the present invention there is provided a combination

- 15 product comprising an anti-angiogenic agent selected from :-
 - 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
 - 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
 - 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
- 20 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
- 25 4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]propoxy}quinazoline,
- 7-(3-(4-acetylpirazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline and
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline,
- 30 6-methoxyquinazoline,
 or a pharmaceutically-acceptable acid-addition salt thereof;
 and a Src kinase inhibitor selected from :-

- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-yloethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 5 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-
- 10 5-isopropoxyquinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)quinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]-6-methoxyquinazoline,
- 15 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,
- 20 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxyquinazoline and
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
- 7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy}-5-isopropoxyquinazoline,
- or a pharmaceutically-acceptable acid-addition salt thereof;
- 25 for use in the production of an anti-cancer effect in a warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

The therapeutic combination product of this aspect of the present invention may be

- 30 administered in the form of a suitable pharmaceutical composition as defined hereinbefore. According to this aspect of the invention there is provided a pharmaceutical composition for use in the production of an anti-tumour effect in a warm-blooded mammal such as a human being which comprises a combination product as defined hereinbefore in association with a

pharmaceutically-acceptable excipient or carrier and characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced

5 Whilst taking account of the fact that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced, the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host
10 treated and the particular route of administration.

Subject to that counter-balancing need, an anti-angiogenic agent as defined hereinbefore will generally be administered chronically so that a daily dose in the range, for example, 0.01 mg/kg to 50 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for
15 example, for intravenous administration, a daily dose in the range, for example, 0.01 mg/kg to 25 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a daily dose in the range, for example, 0.01 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form, to provide a daily dose in the range, for example, 0.01 mg/kg to 10 mg/kg body weight, conveniently 0.01 mg/kg to
20 5 mg/kg body weight.

Subject to that counter-balancing need, a Src kinase inhibitor as defined hereinbefore will generally be administered chronically so that a daily dose in the range, for example, 0.02 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for
25 example, for intravenous administration, a daily dose in the range, for example, 0.01 mg/kg to 30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a daily dose in the range, for example, 0.01 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form, to provide a daily dose in the range, for example, 0.02 mg/kg to 15 mg/kg body weight, conveniently 0.02 mg/kg to
30 5 mg/kg body weight.

It will be appreciated that the pharmaceutical composition according to the present invention includes a pharmaceutical composition comprising a combination product as defined hereinbefore (comprising an anti-angiogenic agent and a Src kinase inhibitor) and a

pharmaceutically-acceptable excipient or carrier. Such a composition conveniently provides the therapeutic combination product of the invention for simultaneous administration.

A pharmaceutical composition according to this aspect of the present invention also includes separate compositions comprising a first composition comprising an anti-angiogenic agent and a pharmaceutically-acceptable excipient or carrier, and a second composition comprising a Src kinase inhibitor and a pharmaceutically-acceptable excipient or carrier. Such a composition conveniently provides the combination product of the invention as defined hereinbefore for sequential or separate administration but the separate compositions may also be administered simultaneously. Conveniently such a pharmaceutical composition of the invention comprises a kit comprising a first container with a suitable composition containing the anti-angiogenic agent and a second container with a suitable composition containing the Src kinase inhibitor.

According to this aspect of the present invention there is provided a kit for use in dosing a combination product as defined hereinbefore to produce an anti-cancer effect in a warm-blooded mammal such as a human being comprising :-

- a) an anti-angiogenic agent together with a pharmaceutically-acceptable excipient or carrier in a first unit dosage form;
- b) a Src kinase inhibitor together with a pharmaceutically-acceptable excipient or carrier in a second unit dosage form; and
- c) container means for containing said first and second dosage forms; and characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

According to the present invention there is also provided a combination product comprising the anti-angiogenic agent 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, and the Src kinase inhibitor 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, for use in the production of an anti-cancer effect in a warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

According to a further aspect of the present invention there is provided the use of a combination product as defined hereinbefore in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

According to a further feature of the present invention there is provided a method for the production of an anti-cancer effect in a warm-blooded mammal such as a human being which comprises the administration of effective amounts of the components of the combination product as defined hereinbefore characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

According to a further feature of the present invention there is provided a method for the production of an anti-cancer effect in a warm-blooded mammal such as a human being which comprises the simultaneous, sequential or separate administration to a warm-blooded mammal such as a human being that is in need of such treatment of effective amounts of the components of the combination product as defined hereinbefore characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

Example

Measurement of blood pressure in conscious rats by radio-telemetry

Blood pressure was measured using commercially-available radio-telemetry equipment (Data Sciences International, Saint Paul, Minnesota, USA) which provides a means for the remote measurement of the blood pressure (BP), heart rate and activity of a conscious, unrestrained laboratory animal such as a rat. Measurements obtained using this system have the advantage that the test animal is free from stresses induced by surgery and/or restraint.

The equipment comprises a pressure transducer (Code No. TA11PA-C40; hereinafter the 'pressure transducer implant') that is implanted into the abdomen of a laboratory rat. The transducer transmits a radio signal indicating the pressure in the aorta of the animal and the signal is detected by a receiver (RA1010) placed under the plastic cage which houses the

animal. The signal is recorded and evaluated automatically by pre-written computer software (DataQuest 2.1 that may be installed on a suitable computer such as an IBM-compatible personal computer containing an Intel™ 486 processor).

Implantation Methodology

5 Each of a group of normotensive rats (Alderley Park strain, male animals) was anaesthetised with 'Fluothane™' inhalation anaesthetic. The abdomen of each rat was shaved and the skin was coated with a topical disinfectant. An incision was made in the outer skin to expose the abdominal muscle wall which was cut along the mid-line and opened. The viscera of the animal was held back with retractors and the abdominal aorta was located. The
10 aorta was cleaned of connective tissue over a 2-3 cm length and carefully separated from the associated vena cava. Care was taken to ensure that the area of aorta prepared was below the renal arteries to avoid any potential occlusion of the kidneys following surgery. The tip of a 21 gauge needle (Micro Lance, Becton Dickinson) was bent to approximately 90 degrees to the needle shaft. A tie was placed loosely under the aorta. The tie was lifted to occlude the
15 blood vessel and the needle was used to form a puncture into the blood vessel. With the needle held in place in the blood vessel, the bevel of the needle was used carefully to control the insertion of the tip of the catheter from the 'pressure transducer implant' into the blood vessel. The needle tip was withdrawn and a small drop of surgical glue (Vet Bond 3M) was run down the catheter to form a seal between the catheter and the blood vessel. A cellulose
20 patch was placed over the seal to stabilise the catheter. The 'pressure transducer implant' was stitched into position on the inside of the abdominal wall and the abdominal muscle wall was closed with absorbable stitches. The ends of the stitches were trimmed and the outer skin of the animal was closed using surgical autoclips which were removed 7 days after surgery.

General Study Protocol

25 The animals were housed in a facility using a 12 hour cycle of light and dark. Normal rat behaviour was seen during the Studies *i.e.* the animals rested during the light phase and were active during the dark phase. Following removal of the surgical autoclips, all rats were handled daily and dosed daily with control vehicle (citrate buffer or 1% polysorbate 80 in water) for a further week in order to acclimatise them to dosing techniques. Blood pressure
30 data were recorded from each animal every 10 minutes throughout each Study. To obtain more reproducible basal blood pressure measurements, data were obtained during the 12 hour light phase when the test animals were inactive.

Typically, on day 1, each of a group of 3 rats was dosed p.o. at approximately 9.00 am with control vehicle and blood pressure data were recorded during the ensuing 24 hour period. The following day, each rat was dosed p.o. at approximately 9.00 am with a suitable dose of a test compound or with a combination of test compounds and blood pressure data were recorded during the ensuing 24 hour period. Doses were selected that provided sufficient blood levels of the test compounds that a sustained effect on blood pressure was obtained indicating that an anti-tumour effect would be obtainable in an appropriate animal model. The difference was calculated between the basal blood pressure on day 1 and the basal blood pressure on day 2 following the dosing of the test compound or combination of test compounds. For single agent Studies, both the maximum effect on blood pressure (in mm Hg compared to blood pressure data in control animals) and the time (in hours) for the restoration of normotension were recorded. For combination Studies, the selected doses of each compound were co-administered and adjusted if necessary to obtain a substantially normotensive effect. Illustrative results are shown in the Figures hereinafter wherein :-

15 VTK-1 is the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline which provides Example 238 of International Patent Application WO 00/47212 and

20 Src-1 is the compound 7-[2-(4-acetylpirperazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline which may be prepared as described hereinafter.

Brief Description of the Drawings

Figure 1 shows the diastolic blood pressure profile following the single dose p.o. at about 25 9.00 am of control citrate buffer vehicle (thinner line) or of 1.5 mg/kg of VTK-1 (thicker line) with time (minutes) plotted on the horizontal axis and diastolic blood pressure (mm Hg) plotted on the vertical axis.

Figure 2 shows the diastolic blood pressure profile following the single dose p.o. at about 30 9.00 am of control citrate buffer vehicle (thinner line) or of 25 mg/kg of Src-1 (thicker line) with time (minutes) plotted on the horizontal axis and diastolic blood pressure (mm Hg) plotted on the vertical axis.

Figure 3 shows the diastolic blood pressure profile following the single dose p.o. at about 9.00 am of control citrate buffer vehicle (thinner line) or of a combination of 1.5 mg/kg of VTK-1 and 25 mg/kg of Src-1 (thicker line) with time (minutes) plotted on the horizontal axis and diastolic blood pressure (mm Hg) plotted on the vertical axis.

5

The data in the Figures show that the contrasting blood pressure effects of the anti-angiogenic agent VTK-1 and the Src kinase inhibitor Src-1 can be substantially counter-balanced.

10 In general, in the following Examples :-

(i) operations were carried out at ambient temperature, i.e. in the range 17 to 25°C and under an atmosphere of an inert gas such as argon unless otherwise stated;

(ii) evaporation were carried out by rotary evaporation *in vacuo* and work-up procedures were carried out after removal of residual solids by filtration;

15 (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany or high pressure liquid chromatography (HPLC) was performed on C18 reverse phase silica, for example on a Dynamax C-18 60Å preparative reversed-phase column;

20 (iv) yields, where present, are not necessarily the maximum attainable;

(v) in general, the end-products have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and/or mass spectral techniques; fast-atom bombardment (FAB) mass spectral data were obtained using a Platform spectrometer and, where appropriate, either positive ion data or negative ion data were collected; NMR

25 chemical shift values were measured on the delta scale [proton magnetic resonance spectra were determined using a Jeol JNM EX 400 spectrometer operating at a field strength of 400MHz, Varian Gemini 2000 spectrometer operating at a field strength of 300MHz or a Bruker AM300 spectrometer operating at a field strength of 300MHz]; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, 30 broad;

(vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, HPLC, infra-red (IR) and/or NMR analysis;

(vii) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the Formula I were determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture;

5 (viii) where certain compounds were obtained as an acid-addition salt, for example a mono hydrochloride salt or a dihydrochloride salt, the stoichiometry of the salt was based on the number and nature of the basic groups in the compound, the exact stoichiometry of the salt was generally not determined, for example by means of elemental analysis data;

(ix) the following abbreviations have been used:-

10	DMF	<u>N,N</u> -dimethylformamide
	DMSO	dimethylsulphoxide
	THF	tetrahydrofuran
	DMA	<u>N,N</u> -dimethylacetamide

15 Example : Preparation of Src-1

7-[2-(4-acetyl

A mixture of 7-(2-chloroethoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline (3.39 g), 1-acetylNMR Spectrum: (CDCl_3) 1.5 (s, 3H), 1.51 (s, 3H), 2.08 (s, 3H), 2.55 (m, 4H), 2.86 (t, 2H), 3.5 (m, 2H), 3.67 (m, 2H), 4.21 (t, 2H), 4.8 (m, 1H), 6.03 (s, 2H), 6.5 (s, 1H), 6.69 (d, 1H), 6.79 (s, 1H), 6.94 (d, 1H), 8.49 (s, 1H), 9.39 (s, 1H); Mass Spectrum: $\text{M}+\text{H}^+$ 528; Elemental Analysis Found: C 59.2; H 6.0; N 13.1; Cl 6.7; $\text{C}_{26}\text{H}_{30}\text{ClN}_5\text{O}_5$ requires C 59.1; H 5.7; N 13.3; Cl 6.7%.

The 7-(2-chloroethoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline used as a starting material was prepared as follows :-

Di-*tert*-butyl azodicarboxylate (28.9 g) was added to a stirred mixture of 7-benzyloxy-5-hydroxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (International Patent Application WO 01/94341, Example 15, Note [8] thereof; 30 g), isopropanol (7.3 ml), triphenylphosphine (32.95 g) and methylene chloride (350 ml) that had been 5 cooled to 0°C. The reaction mixture was allowed to warm to ambient temperature and was stirred for 1.5 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 7-benzyloxy-5-isopropoxy- 3,4-dihydroquinazolin-4-one as a solid (23.8 g); NMR Spectrum: (DMSO_d₆) 7.89 (s, 1H), 10 7.5-7.3 (m, 5H), 6.75 (s, 1H), 6.62 (s, 1H), 5.24 (s, 2H), 4.65 (m, 1H), 1.29 (d, 6H).

Ammonium formate (48.4 g) was added to a stirred mixture of 7-benzyloxy- 5-isopropoxy-3,4-dihydroquinazolin-4-one (23.8 g), 10% palladium-on-carbon catalyst (2.8 g) and DMF (300 ml) and the resultant mixture was stirred at ambient temperature for 2 hours. The mixture was filtered and the filtrate was evaporated. The material so obtained was 15 triturated under water, the pH of which was adjusted to pH7. The solid so obtained was collected by filtration, washed with water and with diethyl ether and dried over phosphorus pentoxide under vacuum. There was thus obtained 7-hydroxy-5-isopropoxy- 3,4-dihydroquinazolin-4-one as a white solid (15.9 g); NMR Spectrum: (DMSO_d₆) 1.3 (d, 6H), 4.57 (m, 1H), 6.42 (s, 1H), 6.5 (s, 1H), 7.8 (s, 1H).

20 A mixture of the material so obtained, acetic anhydride (34 ml) and pyridine (0.62 ml) was heated to 70°C for 30 minutes. The reaction mixture was cooled to ambient temperature and the excess of acetic anhydride was evaporated. The white solid so obtained was added to hot water (80°C, 250 ml) and the mixture was stirred vigorously and heated to 80°C for 20 minutes. The mixture was cooled to ambient temperature and 25 the solid was isolated and dried over phosphorus pentoxide. There was thus obtained 7-acetoxy-5-isopropoxy-3,4-dihydroquinazolin-4-one (17.86 g); NMR Spectrum: (DMSO_d₆) 7.97 (s, 1H), 6.91 (s, 1H), 6.85 (s, 1H), 4.65 (m, 1H), 2.32 (s, 3H), 1.33 (d, 6H).

Phosphorus oxychloride (2.13 ml) was added to a mixture of 7-acetoxy-5-isopropoxy- 30 3,4-dihydroquinazolin-4-one (5 g), N,N-diisopropyl-N-ethylamine (8.62 ml) and 1,2-dichloroethane (140 ml) and the mixture was heated to 75°C for 2.5 hours. The mixture was cooled to ambient temperature and the solvent was evaporated in vacuo to give 7-acetoxy-4-chloro-5-isopropoxyquinazoline which was used without further purification.

A mixture of the material so obtained, 6-chloro-2,3-methylenedioxyaniline (3.27 g; International Patent Application WO 01/94341, Example 17, Note [30]) and isopropanol (45 ml) was stirred and heated to 80°C for 1 hour. The resultant mixture was cooled to ambient temperature and the solvents were evaporated. The residue was 5 partitioned between methylene chloride and a 10% aqueous ammonium hydroxide solution. The organic solution was washed with brine, dried over magnesium sulphate and evaporated. The residue was dissolved in methylene chloride (45 ml) and a 7N solution of ammonia in methanol (45 ml) was added and the mixture was stirred at ambient temperature for 1 hour. After evaporation of the solvents, the residue was 10 purified by column chromatography on silica using initially ethyl acetate and then a 10:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 4-(6-chloro-2,3-methylenedioxyanilino)-7-hydroxy-5-isopropoxyquinazoline as a white solid (3.79 g); NMR Spectrum: (DMSO_d₆) 1.45 (s, 3H), 1.46 (s, 3H), 4.93 (m, 1H), 6.08 (s, 2H), 6.67 (m, 2H), 6.9 (d, 1H), 7.07 (d, 1H), 8.28 (s, 1H), 9.28 (s, 1H).

15 A mixture of the material so obtained, 1,2-dichloroethane (55 ml) and potassium carbonate (2.52 g) was stirred and heated to 80°C for 24 hours. The mixture was cooled to ambient temperature and the solvent was evaporated. The residue was diluted with methylene chloride and insoluble material was filtered off. The filtrate was evaporated and the residue was purified by column chromatography on silica using a 20:1 mixture of 20 methylene chloride and methanol as eluent. There was thus obtained 7-(2-chloroethoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline (3.39 g); NMR Spectrum: (CDCl₃) 1.54 (s, 3H), 1.55 (s, 3H), 3.88 (t, 2H), 4.36 (t, 2H), 4.84 (m, 1H), 6.05 (s, 2H), 6.56 (s, 1H), 6.71 (d, 1H), 6.79 (s, 1H), 6.97 (d, 1H), 8.54 (s, 1H), 9.42 (s, 1H); Mass Spectrum: M+H⁺ 436.

25

Src Inhibitors described within European Patent Application No. 02292736.2

Example 1

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-(3-chloropropoxy)-30 6-methoxyquinazoline

Sodium hexamethyldisilazane (1M solution in THF; 0.734 ml) was added to a solution of 4-amino-5-chloro-2,3-methylenedioxypyridine (0.12 g) in DMF (4 ml) that had been cooled to 0°C and the mixture was stirred for 15 minutes. A portion (0.1 g) of 4-chloro-

7-(3-chloropropoxy)-6-methoxyquinazoline was added and the resultant mixture was stirred and allowed to warm to ambient temperature. The mixture was stirred at ambient temperature for 16 hours. The reaction mixture was evaporated and the residue was partitioned between methylene chloride and a saturated aqueous ammonium chloride solution. The organic phase
5 was washed with water and with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent followed by increasingly polar mixtures of methylene chloride and acetonitrile. There was thus obtained the title compound as a white foam (0.11 g); NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 2.3 (m, 2H), 3.8 (m, 2H), 4.05 (s,
10 3H), 4.4 (t, 2H), 6.3 (s, 2H), 7.4 (s, 1H), 7.9 (s, 1H), 8.15 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 423 and 425.

The 4-amino-5-chloro-2,3-methylenedioxypyridine used as a starting material was prepared as follows :-

Bromochloromethane (20 ml) was added to a mixture 5-chloro-2,3-dihydroxypyridine
15 (30 g), caesium carbonate (100 g) and DMF (300 ml) and the mixture was stirred and heated to 90°C for 3.5 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by column chromatography on silica using methylene chloride as eluent. There was thus obtained 5-chloro-
2,3-methylenedioxypyridine as a white solid (4.7 g); NMR Spectrum: (DMSO_d₆) 6.25 (s, 2H),
20 7.5 (s, 1H), 7.65 (s, 1H).

A mixture of diisopropylamine (8.2 ml) and THF (100 ml) was cooled to -70°C and n-butyllithium (2.5 M in hexane, 24 ml) was added dropwise. The mixture was stirred at -70°C for a further 20 minutes. A solution of 5-chloro-2,3-methylenedioxypyridine (4.2 g) in THF (40 ml) was added over 10 minutes and the reaction mixture was stirred at -70°C for
25 1 hour. Dry carbon dioxide gas was bubbled into the reaction mixture for 30 minutes. The resultant reaction mixture was allowed to warm to ambient temperature. Water (20 ml) was added and the organic solvent was evaporated. The residue was acidified to pH2 by the addition of 1N aqueous hydrochloric acid solution. The resultant solid was isolated and washed in turn with water and diethyl ether and dried under vacuum at 40°C. There was thus
30 obtained 5-chloro-2,3-methylenedioxypyridine-4-carboxylic acid (3.6 g); ¹³C NMR Spectrum: (DMSO_d₆) 103, 120, 121, 138, 140, 158, 163.

A mixture of the material so obtained, diphenylphosphoryl azide (3.6 ml), anhydrous tert-butanol (13.5 ml), triethylamine (4.2 ml) and 1,4-dioxane (63 ml) was stirred and heated

to 100°C for 3 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with water, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 9:1 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained 5 tert-butyl 5-chloro-2,3-methylenedioxypyrid-4-ylcarbamate (3.8 g); NMR Spectrum: (DMSO_d₆) 1.45 (s, 9H), 6.2 (s, 2H), 7.7 (s, 1H), 9.2 (s, 1H).

The material so obtained was dissolved in methylene chloride (35 ml) and the solution was cooled to 0°C. Trifluoroacetic acid (15 ml) was added and the mixture was stirred at 0°C for 3 hours. The mixture was allowed to warm to ambient temperature and was stirred for 16 10 hours. The solvent was evaporated and the residue was diluted with ice water and neutralised to pH7 by the addition of 2N aqueous sodium hydroxide solution whilst keeping the mixture temperature at 0°C. The resultant mixture was extracted with methylene chloride and the extract dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 19:1 mixture of methylene chloride and diethyl ether as 15 eluent. There was thus obtained 4-amino-5-chloro-2,3-methylenedioxypyridine (2 g); NMR Spectrum: (DMSO_d₆) 6.1 (s, 2H), 6.2 (s, 2H), 7.45 (s, 1H); ¹³C NMR Spectrum: (DMSO_d₆) 100, 112, 125, 136, 138, 157; Mass Spectrum: M+H⁺ 173.

The 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline used as a starting material was prepared as follows :-

20 Ammonium formate (45 g) was added portionwise over 1.25 hours to a stirred mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (International Patent Application WO 02/16352, Example 1 thereof; 20 g), 10% palladium-on-carbon catalyst (3.3 g) and DMF (530 ml) and the reaction mixture was stirred for an additional 30 minutes. The catalyst was removed by filtration and the solvent was evaporated. There was thus obtained 7-hydroxy- 25 6-methoxy-3,4-dihydroquinazolin-4-one (8.65 g); NMR Spectrum: (DMSO_d₆) 3.9 (s, 3H), 7.0 (s, 1H), 7.45 (s, 1H), 7.9 (s, 1H).

A mixture of the material so obtained, acetic anhydride (63 ml) and pyridine (7.5 ml) was heated to 100°C for 4.5 hours. The resultant mixture was allowed to stand at ambient temperature for 16 hours. The mixture was poured into a stirred mixture (400 ml) of ice and 30 water. The resultant precipitate was isolated and dried under vacuum. Analysis revealed that hydrolysis of the acetate group on the 4 position of the quinazoline was incomplete. The mixture was therefore further hydrolysed with water (150 ml) and pyridine (a few drops) at 90°C for 15 minutes. The resultant mixture was cooled to ambient temperature and the solid

was collected by filtration, washed with water and dried under vacuum. There was thus obtained 7-acetoxy-6-methoxy-3,4-dihydroquinazolin-4-one (7.4 g); NMR Spectrum: (DMSO_d₆) 2.3 (s, 3H), 3.9 (s, 3H), 7.45 (s, 1H), 7.65 (s, 1H), 8.05 (s, 1H).

A mixture of a portion (2 g) of the material so obtained, thionyl chloride (32 ml) and 5 DMF (5 drops) was stirred and heated to reflux for 1.5 hours. The mixture was cooled to ambient temperature and the excess of thionyl chloride was evaporated. Toluene was added to the residue and evaporated. The resultant residue was diluted with methylene chloride (15 ml) and a 10% ammonia solution in methanol (80 ml) was added and the mixture was heated to 80°C for 10 minutes. The mixture was cooled to ambient temperature and 10 evaporated. Water was added to the residue and the mixture was neutralised by the addition of dilute aqueous hydrochloric acid solution. The resultant precipitate was collected by filtration and dried under vacuum at 35°C for 16 hours. There was thus obtained 4-chloro-7-hydroxy-6-methoxyquinazoline (1.65 g); NMR Spectrum: (DMSO_d₆) 4.0 (s, 3H), 7.25 (s, 1H), 7.4 (s, 1H), 8.8 (s, 1H).

15 Di-tert-butyl azodicarboxylate (2.3 g) was added portionwise over a few minutes to a stirred mixture of 4-chloro-7-hydroxy-6-methoxyquinazoline (1.65 g), 3-chloropropanol (0.7 ml), triphenylphosphine (2.6 g) and methylene chloride (100 ml) and the reaction mixture was stirred at ambient temperature for 2 hours. The mixture was concentrated to a volume of about 30 ml by evaporation and the residue was purified by column chromatography on silica 20 using increasingly polar mixtures of petroleum ether (b.p 40-60°C) and ethyl acetate as eluent. There was thus obtained 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline as a white solid (2 g); NMR Spectrum: (DMSO_d₆) 2.3 (m, 2H), 3.8 (m, 2H), 4.05 (s, 3H), 4.4 (m, 2H), 7.45 (s, 1H), 7.55 (s, 1H), 8.9 (s, 1H).

25 Example 2

7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxyquinazoline

Using an analogous procedure to that described in Example 1, 4-chloro-7-(2-chloroethoxy)-6-methoxyquinazoline was reacted with 4-amino-5-chloro-30 2,3-methylenedioxypyridine to give the title compound in 92% yield; NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 4.05 (s, 3H), 4.1 (t, 2H), 4.55 (t, 2H), 6.3 (s, 2H), 7.4 (s, 1H), 7.9 (s, 1H), 8.15 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 409 and 411.

The 4-chloro-7-(2-chloroethoxy)-6-methoxyquinazoline used as a starting material was prepared as follows :-

1,2-Dichloroethane (400 ml) was added to a stirred mixture of 7-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (International Patent Application
5 WO 02/16352, Example 2, Note [4] thereof; 85 g), potassium carbonate (77 g) and DMF (400 ml) and the reaction mixture was heated to 70°C for 16 hours. The reaction mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the solid so obtained was washed with water and dried over phosphorus pentoxide at 50°C. The material so obtained was purified by column chromatography on silica using increasingly polar
10 mixtures of methylene chloride and ethyl acetate as eluent. There was thus obtained 7-(2-chloroethoxy)-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one as a white solid (65.6 g); NMR Spectrum: (CDCl_3) 1.2 (s, 9H), 3.9 (t, 2H), 4.0 (s, 3H), 4.4 (t, 2H), 5.95 (s, 2H), 7.1 (s, 1H), 7.7 (s, 1H), 8.2 (s, 1H); Mass Spectrum: $M+H^+$ 369 and 371.

A mixture of the material so obtained and a saturated solution of ammonia gas in
15 methanol (1.6 L) was stirred at ambient temperature for 2 days. The solvent was concentrated by evaporation to about one-fourth of the original volume and the precipitate was collected by filtration and washed with diethyl ether. There was thus obtained 7-(2-chloroethoxy)-
6-methoxy-3,4-dihydroquinazolin-4-one as a white solid (44 g); NMR Spectrum: (DMSO_d_6) 3.9 (s, 3H), 4.05 (t, 2H), 4.4 (t, 2H), 7.15 (s, 1H), 7.45 (s, 1H), 8.0 (s, 1H); Mass Spectrum:
20 $M+H^+$ 255 and 257.

A mixture of a portion (5 g) of the material so obtained, thionyl chloride (28 ml) and DMF (0.7 ml) was stirred and heated to 80°C for 1.5 hours. The excess of thionyl chloride was evaporated and toluene was added and evaporated. The residual solid was suspended in a mixture of ice and water and basified to pH7.5 by the addition of 2N aqueous sodium
25 hydroxide solution followed by a saturated aqueous sodium bicarbonate solution. The resultant solid was collected by filtration, washed with water and diethyl ether and dried over phosphorus pentoxide under vacuum. The material so obtained was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and acetonitrile as eluent. There was thus obtained 4-chloro-7-(2-chloroethoxy)-
30 6-methoxyquinazoline (3.06 g; NMR Spectrum: (CDCl_3) 3.95 (t, 2H), 4.1 (s, 3H), 4.5 (t, 2H), 7.35 (s, 1H), 7.45 (s, 1H), 8.9 (s, 1H); Mass Spectrum: $M+H^+$ 273 and 275.

Example 3

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxy-

7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline

A mixture of 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-(3-chloropropoxy)-

- 5 6-methoxyquinazoline (0.08 g), 1-prop-2-ynylpiperazine (0.047 g), potassium iodide (0.01 g) and DMA (2 ml) was stirred and heated to 80°C for 3.5 hours. The solvent was evaporated and the residue was partitioned between methylene chloride and a saturated aqueous ammonium chloride solution. The organic phase was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 19:1
10 mixture of methylene chloride and methanol and then a 9:1 mixture of methylene chloride and a saturated methanolic ammonia solution as eluent. The resulting gum was triturated under diethyl ether. There was thus obtained the title compound as a solid (0.066 g); NMR Spectrum: (DMSO_d₆ and CF₃CO₂D) 2.3 (m, 2H), 3.2-3.6 (br m, 10H), 3.75 (s, 1H), 3.95 (br s, 2H), 4.0 (s, 3H), 4.35 (m, 2H), 6.3 (s, 2H), 7.4 (s, 1H), 7.9 (s, 1H), 8.15 (s, 1H), 8.95 (s, 1H);
15 Mass Spectrum: M+H⁺ 511 and 513.

The 1-prop-2-ynylpiperazine used as a starting material was prepared as follows :-

- Propargyl bromide (80% solution in toluene; 40 ml) was added dropwise during 10 minutes to a stirred mixture of 1-tert-butoxycarbonylpiperazine (50 g), potassium carbonate (74.2 g) and acetonitrile (2 L) that had been cooled to 0°C. The mixture was stirred
20 for 1.5 hours and allowed to warm to ambient temperature. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. There was thus obtained tert-butyl 4-prop-2-ynylpiperazine-1-carboxylate as an oil (45.5 g); NMR Spectrum: (CDCl₃) 1.4 (s, 9H), 2.2 (s, 1H), 2.45 (m, 4H), 3.3 (s, 2H), 3.45 (m, 4H).

- 25 A solution of the material so obtained in methylene chloride (100 ml) was added slowly to a solution of hydrogen chloride gas in 1,4-dioxane (4M, 450 ml). The reaction was slightly exothermic and a precipitate formed as carbon dioxide gas was evolved. The mixture was stirred at ambient temperature for 1 hour. The resultant mixture was evaporated and the residue was suspended in methylene chloride. A solution of ammonia gas in methanol (7M, 30 110 ml) was added and the mixture was stirred at ambient temperature for 15 minutes. The mixture was filtered and the filtrate was evaporated. An oil was obtained which crystallised on standing. There was thus obtained 1-prop-2-ynylpiperazine (23 g); NMR Spectrum: (CDCl₃) 2.2 (s, 1H), 2.5 (br s, 4H), 2.85 (m, 4H), 3.25 (s, 2H).

Example 4**7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
5-tetrahydropyran-4-yloxyquinazoline**

5 Using an analogous procedure to that described in Example 1, 4-chloro-
 7-(2-chloroethoxy)-5-tetrahydropyran-4-yloxyquinazoline was reacted with 4-amino-5-chloro-
 2,3-methylenedioxypyridine to give the title compound in 37% yield; NMR Spectrum:
 (CDCl₃) 2.0 (m, 2H), 2.3 (m, 2H), 3.65 (m, 2H), 3.9 (m, 2H), 4.1 (m, 2H), 4.4 (m, 2H), 4.8
 (m, 1H), 6.2 (s, 2H), 6.65 (s, 1H), 6.9 (s, 1H), 7.8 (s, 1H), 8.6 (s, 1H), 9.5 (s, 1H); Mass
 Spectrum: M+H⁺ 479 and 481.

The 4-chloro-7-(2-chloroethoxy)-5-tetrahydropyran-4-yloxyquinazoline used as a
 starting material was prepared as follows :-

Di-tert-butyl azodicarboxylate (0.338 g) was added to a stirred mixture of 4-chloro-
 7-hydroxy-5-tetrahydropyran-4-yloxyquinazoline (International Patent Application

15 WO 01/94341, Example 15, Note [10] thereof; 0.25 g), 2-chloroethanol (0.073 ml),
 triphenylphosphine (0.385 g) and methylene chloride (15 ml) and the reaction mixture was
 stirred at ambient temperature for 1 hour. The mixture was concentrated to a volume of about
 5 ml by evaporation and the residue was purified by column chromatography on silica using
 increasingly polar mixtures of petroleum ether (b.p 40-60°C) and ethyl acetate as eluent.
 20 There was thus obtained 4-chloro-7-(2-chloroethoxy)-5-tetrahydropyran-4-yloxyquinazoline
 as a solid (0.17 g); NMR Spectrum: (CDCl₃) 2.0 (m, 2H), 2.15 (m, 2H), 3.7 (m, 2H), 3.95 (t,
 2H), 4.1 (m, 2H), 4.4 (t, 2H), 4.8 (m, 1H), 6.7 (s, 1H), 6.95 (s, 1H), 8.85 (s, 1H).

Example 5**7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
5-isopropoxyquinazoline**

Using an analogous procedure to that described in Example 1, 4-chloro-
 7-(2-chloroethoxy)-5-isopropoxyquinazoline was reacted with 4-amino-5-chloro-
 2,3-methylenedioxypyridine to give the title compound in 86% yield; NMR Spectrum:
 (CDCl₃) 1.55 (d, 6H), 3.9 (t, 2H), 4.4 (t, 2H), 4.9 (m, 1H), 6.2 (s, 2H), 6.6 (s, 1H), 6.85 (s,
 1H), 7.75 (s, 1H), 8.6 (s, 1H), 9.65 (s, 1H); Mass Spectrum: M+H⁺ 437 and 439.

The 4-chloro-7-(2-chloroethoxy)-5-isopropoxyquinazoline used as a starting material
 was prepared as follows :-

Di-*tert*-butyl azodicarboxylate (28.9 g) was added to a stirred mixture of 7-benzyloxy-5-hydroxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (International Patent Application WO 01/94341, Example 15, Note [8] thereof; 30 g), isopropanol (7.3 ml), triphenylphosphine (32.95 g) and methylene chloride (350 ml) that had been 5 cooled to 0°C. The reaction mixture was allowed to warm to ambient temperature and was stirred for 1.5 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 7-benzyloxy-5-isopropoxy-3,4-dihydroquinazolin-4-one as a solid (23.8 g); NMR Spectrum: (DMSO_d₆) 7.89 (s, 1H), 10 7.5-7.3 (m, 5H), 6.75 (s, 1H), 6.62 (s, 1H), 5.24 (s, 2H), 4.65 (m, 1H), 1.29 (d, 6H).

Ammonium formate (48.4 g) was added to a stirred mixture of 7-benzyloxy-5-isopropoxy-3,4-dihydroquinazolin-4-one (23.8 g), 10% palladium-on-carbon catalyst (2.8 g) and DMF (300 ml) and the resultant mixture was stirred at ambient temperature for 2 hours. The mixture was filtered and the filtrate was evaporated. The material so obtained was 15 triturated under water, the pH of which was adjusted to pH7. The solid so obtained was collected by filtration, washed with water and with diethyl ether and dried over phosphorus pentoxide under vacuum. There was thus obtained 7-hydroxy-5-isopropoxy-3,4-dihydroquinazolin-4-one as a white solid (15.9 g); NMR Spectrum: (DMSO_d₆) 1.3 (d, 6H), 4.57 (m, 1H), 6.42 (s, 1H), 6.5 (s, 1H), 7.8 (s, 1H).

20 A mixture of the material so obtained, acetic anhydride (34 ml) and pyridine (0.62 ml) was heated to 70°C for 30 minutes. The reaction mixture was cooled to ambient temperature and the excess of acetic anhydride was evaporated. The white solid so obtained was added to hot water (80°C, 250 ml) and the mixture was stirred vigorously and heated to 80°C for 20 minutes. The mixture was cooled to ambient temperature and 25 the solid was isolated and dried over phosphorus pentoxide. There was thus obtained 7-acetoxy-5-isopropoxy-3,4-dihydroquinazolin-4-one (17.86 g); NMR Spectrum: (DMSO_d₆) 7.97 (s, 1H), 6.91 (s, 1H), 6.85 (s, 1H), 4.65 (m, 1H), 2.32 (s, 3H), 1.33 (d, 6H).

A mixture of a portion (5.4 g) of the material so obtained, triphenylphosphine (10.8 g), 30 carbon tetrachloride (12 ml) and 1,2-dichloroethane (50 ml) was stirred and heated to 70°C for 2 hours. The mixture was cooled to ambient temperature and the solvent was evaporated. The residue was dissolved in a 0.5M solution of ammonia gas in 1,4-dioxane (250 ml) and the mixture was heated to 70°C for 10 minutes. The solvent was evaporated and the residue was

cooled in an ice-water bath. Methylene chloride and water were added and the aqueous layer was brought to pH7 by the addition of dilute aqueous hydrochloric acid. The mixture was filtered. The organic phase was dried over magnesium sulphate and evaporated to give 4-chloro-7-hydroxy-5-isopropoxyquinazoline as a foam which was used without further 5 purification.


Di-*tert*-butyl azodicarboxylate (7.9 g) was added to a stirred mixture of the 4-chloro-7-hydroxy-5-isopropoxyquinazoline so obtained, 2-chloroethanol (1.5 ml), triphenylphosphine (8 g) and methylene chloride (200 ml) and the reaction mixture was stirred at ambient temperature for 4 hours. The mixture was concentrated by evaporation and the residue was 10 purified by column chromatography on silica using increasingly polar mixtures of petroleum ether (b.p 40-60°C) and ethyl acetate as eluent. There was thus obtained 4-chloro-7-(2-chloroethoxy)-5-isopropoxyquinazoline (2.5 g); NMR Spectrum: (CDCl₃) 1.45 (d, 6H), 3.9 (t, 2H), 4.4 (t, 2H), 4.75 (m, 1H), 6.65 (s, 1H), 6.9 (s, 1H), 8.8 (s, 1H).

15 Example 6

Using an analogous procedure to that described in Example 3, the appropriate 7-haloalkoxyquinazoline was reacted with the appropriate heterocyclic compound to give the compounds described in Table I. Unless otherwise stated, each compound described in Table I was obtained as a free base.

20

Table I



Compound No. & Note	(R ¹) _m	(R ³) _n
[1]	6-methoxy-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]	5-chloro
[2]	6-methoxy-	5-chloro

	7-[3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy}	
[3]	6-methoxy-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]	5-chloro
[4]	5-tetrahydropyran-4-yloxy- 7-[2-(4-acetylpiperazin-1-yl)ethoxy]	5-chloro
[5]	5-tetrahydropyran-4-yloxy- 7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrrolidin-1-yl]ethoxy}	5-chloro
[6]	5-isopropoxy-7-[2-(4-acetylpiperazin-1-yl)ethoxy]	5-chloro
[7]	5-isopropoxy- 7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrrolidin-1-yl]ethoxy}	5-chloro

Notes

[1] The reactants were 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-(3-chloropropoxy)-6-methoxyquinazoline and 1-isobutyrylpiperazine. The reaction mixture was heated to 120°C for 3 hours. The reaction product was purified by column chromatography on a C18 reversed phase silica column (Waters Symmetry column, 5 microns silica, 19 mm diameter, 100 mm length) using a decreasingly polar mixture of water and acetonitrile (containing 1% acetic acid) as eluent. The material so obtained was dissolved in methylene chloride and an ion exchange resin (diethylaminopolystyrene resin, 4 equivalents) was added and the mixture was stirred for 30 minutes. The mixture was filtered and the filtrate was evaporated. The resultant residue was triturated under pentane to give the required product in 51% yield which gave the following characterising data; NMR Spectrum: (CDCl_3) 1.1 (d, 6H), 2.1 (m, 2H), 2.45 (m, 4H), 2.55 (m, 2H), 2.75 (m, 1H), 3.5 (m, 2H), 3.6 (m, 2H), 4.0 (s, 3H), 4.25 (t, 2H), 6.1 (s, 2H), 7.1 (br s, 1H), 7.3 (s, 1H), 7.75 (s, 1H), 8.7 (br s, 1H); Mass Spectrum: $M+H^+$ 543 and 545.

The 1-isobutyrylpiperazine used as a starting material was prepared as follows :-

Isobutyryl chloride (3.25 ml) was added dropwise to a stirred mixture of 1-benzylpiperazine (5 g), triethylamine (4.35 ml) and methylene chloride (75 ml) which was cooled to 0°C. The reaction mixture was allowed to warm to ambient temperature and stirred for 1 hour. The mixture was partitioned between methylene chloride and water. The organic phase was washed with water and with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 3:2 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained 1-benzyl-

4-isobutyrylpiperazine (5.95 g) as an oil; NMR Spectrum: (CDCl₃) 1.1 (d, 6H), 2.45 (m, 4H), 2.8 (m, 1H), 3.5 (m, 4H), 3.65 (m, 2H), 7.3 (m, 5H); Mass Spectrum: M+H⁺ 247.

A mixture of the material so obtained, cyclohexene (70 ml), palladium oxide-on-carbon catalyst (20%; 1.1 g) and ethanol (120 ml) was stirred and heated to 80°C for 3 hours.

- 5 The catalyst was removed by filtration and the solvent was evaporated to give 1-isobutyrylpiperazine (3.7 g) as a solid; NMR Spectrum: (CDCl₃) 1.05 (d, 6H), 2.75 (m, 1H), 2.8 (m, 4H), 3.45 (m, 2H), 3.55 (m, 2H).
- [2] The reactants were 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-(3-chloropropoxy)-6-methoxyquinazoline and 1-(2,2,2-trifluoroethyl)piperazine. The 10 reaction mixture was heated to 120°C for 3 hours. The reaction product was purified by column chromatography on a C18 reversed phase silica column (Waters Symmetry column, 5 microns silica, 19 mm diameter, 100 mm length) using a decreasingly polar mixture of water and acetonitrile (containing 1% acetic acid) as eluent. The material so obtained was dissolved in methylene chloride and an ion exchange resin (diethylaminopolystyrene resin, 15 4 equivalents) was added and the mixture was stirred for 30 minutes. The mixture was filtered and the filtrate was evaporated. The resultant residue was triturated under pentane to give the required product in 72% yield which gave the following characterising data; NMR Spectrum: (CDCl₃) 2.1 (m, 2H), 2.5 (m, 6H), 2.7 (m, 4H), 2.95 (q, 2H), 4.05 (s, 3H), 4.25 (t, 2H), 6.1 (s, 2H), 7.1 (br s, 1H), 7.3 (s, 1H), 7.75 (s, 1H), 8.35 (br s, 1H); Mass Spectrum: 20 M+H⁺ 555 and 557; Elemental Analysis: Found C, 51.8; H, 5.0; N, 14.8; C₂₄H₂₆ClF₃N₆O₄ requires C, 51.9; H, 4.7; N, 15.1%.

The 1-(2,2,2-trifluoroethyl)piperazine used as a starting material was prepared as follows :-

- 22,2,2-Trifluoroethyl trifluoromethanesulphonate (8.2 g) was added to a stirred mixture 25 of 1-tert-butoxycarbonylpiperazine (6 g), potassium carbonate (5.77 g) and acetonitrile (30 ml) and the resultant mixture was stirred at ambient temperature for 16 hours. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of petroleum ether (b.p 40-60°C) and ethyl acetate as eluent. There was thus obtained tert-butyl 30 4-(2,2,2-trifluoroethyl)piperazine-1-carboxylate as a solid (8.1 g); NMR Spectrum: (CDCl₃) 1.45 (s, 9H), 2.6 (m, 4H), 2.95 (q, 2H), 3.4 (m, 4H).

Hydrogen chloride gas was bubbled through a solution of tert-butyl 4-(2,2,2-trifluoroethyl)piperazine-1-carboxylate (8 g) in ethyl acetate (50 ml) during 1.5 hours.

A precipitate formed as carbon dioxide gas was evolved. The precipitate was collected by filtration, washed with ethyl acetate and dried under vacuum. There was thus obtained 1-(2,2,2-trifluoroethyl)piperazine hydrochloride (7 g); NMR Spectrum: (DMSO_d₆ and CF₃CO₂D) 2.85 (m, 4H), 3.1 (m, 4H), 3.35 (q, 2H).

5 The material so obtained was suspended in methylene chloride and a saturated methanolic ammonia solution (20 ml) was added. The resultant mixture was stirred at ambient temperature for 20 minutes. The mixture was filtered and the filtrate was evaporated at ambient temperature under vacuum. There was thus obtained

1-(2,2,2-trifluoroethyl)piperazine which was used without any additional purification.

10 [3] The reactants were 7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxyquinazoline and 1-prop-2-ynylpiperazine. The required product was obtained in 52% yield and gave the following characterising data; NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 3.3 (br s, 4H), 3.6 (br s, 4H), 3.75 (br s, 3H), 3.95 (s, 2H), 4.05 (s, 3H), 4.65 (t, 2H), 6.3 (s, 2H), 7.5 (s, 1H), 7.9 (s, 1H), 8.2 (s, 1H), 9.0 (s, 1H); Mass Spectrum:

15 M+H⁺ 497 and 499; Elemental Analysis: Found C, 56.3; H, 5.4; N, 16.2; C₂₄H₂₅ClN₆O₄ 0.7H₂O requires C, 56.6; H, 5.2; N, 16.5%.

[4] The reactants were 7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline and 1-acetyl piperazine. The reaction mixture was heated to 80°C for 3 hours and then to 110°C for 5 hours. The reaction product
20 was purified by column chromatography on a C18 reversed phase silica column (Waters Symmetry column, 5 microns silica, 19 mm diameter, 100 mm length) using a decreasingly polar mixture of water and acetonitrile (containing 1% acetic acid) as eluent. The organic solvents were evaporated and the pH of the aqueous phase was adjusted to 7.5. The solution was extracted with methylene chloride and the organic phase was dried over magnesium sulphate and evaporated. The resultant residue was triturated under diethyl ether to give the required product in 45% yield which gave the following characterising data; NMR Spectrum: (CDCl₃) 2.0 (m, 2H), 2.1 (s, 3H), 2.3 (m, 2H), 2.6 (m, 4H), 2.95 (m, 2H), 3.55 (m, 2H), 3.65 (m, 4H), 4.1 (m, 2H), 4.3 (m, 2H), 4.8 (m, 1H), 6.2 (s, 2H), 6.6 (s, 1H), 6.9 (s, 1H), 7.8 (s, 1H), 8.65 (s, 1H), 9.5 (s, 1H); Mass Spectrum: M+H⁺ 571 and 573; Elemental Analysis:

30 Found C, 55.3; H, 5.4; N, 13.9; C₂₇H₃₁ClN₆O₆ 1H₂O requires C, 55.1; H, 5.7; N, 14.3.

[5] The reactants were 7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline and (3RS,4SR)-3,4-methylenedioxypyrrolidine. The reaction mixture was heated to 80°C for

3 hours and then to 110°C for 5 hours. The reaction product was purified by column chromatography on a C18 reversed phase silica column (Waters Symmetry column, 5 microns silica, 19 mm diameter, 100 mm length) using a decreasingly polar mixture of water and acetonitrile (containing 1% acetic acid) as eluent. The organic solvents were evaporated and
5 the pH of the aqueous phase was adjusted to 7.5. The solution was extracted with methylene chloride and the organic phase was dried over magnesium sulphate and evaporated. The resultant residue was triturated under diethyl ether to give the required product in 69% yield which gave the following characterising data; NMR Spectrum: (CDCl₃) 2.0 (m, 2H), 2.3 (m, 2H), 2.4 (m, 2H), 2.3 (t, 2H), 3.3 (d, 2H), 3.55 (m, 2H), 4.1 (m, 2H), 4.3 (t, 2H), 4.65 (m, 2H),
10 4.8 (m, 1H), 4.9 (s, 1H), 5.2 (s, 1H), 6.2 (s, 2H), 6.6 (s, 1H), 6.9 (s, 1H), 7.8 (s, 1H), 8.65 (s, 1H), 9.5 (s, 1H); Mass Spectrum: M+H⁺ 558 and 560; Elemental Analysis: Found C, 56.5; H, 5.3; N, 12.5; C₂₆H₂₈ClN₅O₇ 0.2Et₂O requires C, 56.2; H, 5.3; N, 12.2%.

The (3RS,4SR)-3,4-methylenedioxypyrrolidine used as a starting material was prepared as follows :-

15 A solution of di-tert-butyl dicarbonate (Boc₂O, 78.95 g) in ethyl acetate (125 ml) was added dropwise to a stirred mixture of 3-pyrroline (25 g; 65% pure containing pyrrolidine) and ethyl acetate (125 ml) which had been cooled to 0°C. The reaction temperature was maintained at 5-10°C during the addition. The resultant reaction mixture was allowed to warm to ambient temperature overnight. The reaction mixture
20 was washed successively with water, 0.1N aqueous hydrochloric acid solution, water, a saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulphate and evaporated. There was thus obtained, as a colorless oil (62 g), a 2:1 mixture of tert-butyl 3-pyrroline-1-carboxylate, NMR: (CDCl₃) 1.45 (s, 9H), 4.1 (d, 4H), 6.75 (m, 2H), and tert-butyl pyrrolidine-1-carboxylate, NMR: (CDCl₃) 1.5 (s, 9H), 1.8 (br s, 4H),
25 3.3 (br s, 4H).

A solution of the mixture of materials so obtained in acetone (500 ml) was added dropwise to a mixture of N-methylmorpholine-N-oxide (28.45 g), osmium tetroxide (1 g) and water (500 ml) whilst keeping the reaction temperature below 25°C. The reaction mixture was then stirred at ambient temperature for 5 hours. The solvent was evaporated and the
30 residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of petroleum ether (b.p. 40-60°C) and ethyl acetate as eluent and by further column chromatography on silica using increasingly

polar mixtures of methylene chloride and methanol. There was thus obtained tert-butyl (3RS,4SR)-3,4-dihydroxypyrrolidine-1-carboxylate as an oil (34.6 g); NMR Spectrum: (CDCl₃) 1.45 (s, 9H), 2.65 (m, 2H), 3.35 (m, 2H), 3.6 (m, 2H), 4.25 (m, 2H).

A solution of tert-butyl (3RS,4SR)-3,4-dihydroxypyrrolidine-1-carboxylate (34.6 g) in 5 DMF (400 ml) was cooled to 0-5°C and sodium hydride (60% dispersion in mineral oil, 0.375 mol) was added portionwise. The reaction mixture was stirred at 5°C for 1 hour. Dibromomethane (15.6 ml) was added and the reaction mixture was stirred at 5°C for 30 minutes. The reaction mixture was allowed to warm to ambient temperature and was stirred for 16 hours. The DMF was evaporated and the residue was partitioned between ethyl 10 acetate and water. The organic phase was washed with water and with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of petroleum ether (b.p. 40-60°C) and ethyl acetate as eluent. There was thus obtained tert-butyl (3RS,4SR)-3,4-methylenedioxypyrrolidine-1-carboxylate as a colourless oil (19.77 g); NMR Spectrum: (CDCl₃) 1.45 (s, 9H), 3.35 (m, 15 2H), 3.75 (br s, 2H), 4.65 (m, 2H), 4.9 (s, 1H), 5.1 (s, 1H).

A cooled 5M solution of hydrogen chloride in isopropanol (150 ml) was added to a solution of tert-butyl (3RS,4SR)-3,4-methylenedioxypyrrolidine-1-carboxylate (19.7 g) in methylene chloride (500 ml) that was cooled in an ice bath. The reaction mixture was allowed to warm to ambient temperature and was stirred for 4 hours. The solvent was evaporated and 20 the residue was triturated under diethyl ether. The precipitate was collected by filtration, washed with diethyl ether and dried. There was thus obtained (3RS,4SR)-3,4-methylenedioxypyrrolidine hydrochloride as a beige solid (13.18 g); NMR Spectrum: (DMSO_d₆) 3.15 (m, 2H), 3.35 (m, 2H), 4.65 (s, 1H), 4.8 (m, 2H), 5.1 (s, 1H).

The material so obtained was suspended in diethyl ether and a saturated methanolic 25 ammonia solution was added. The resultant mixture was stirred at ambient temperature for 10 minutes. The mixture was filtered and the solvent was evaporated at ambient temperature under vacuum. There was thus obtained (3RS,4SR)-3,4-methylenedioxypyrrolidine which was used without any additional purification.

[6] The reactants were 7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyrid-30 4-ylamino)-5-isopropoxyquinazoline and 1-acetyl piperazine. The reaction mixture was heated to 85°C for 8 hours. The reaction product was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. The product was obtained in 89% yield and gave the following characterising data; NMR Spectrum:

(CDCl₃) 1.55 (d, 6H), 2.1 (s, 3H), 2.6 (m, 4H), 2.9 (t, 2H), 3.5 (t, 2H), 3.7 (t, 2H), 4.25 (t, 2H),

4.85 (m, 1H), 6.15 (s, 2H), 6.55 (s, 1H), 6.85 (s, 1H), 7.75 (s, 1H), 8.6 (s, 1H), 9.6 (s, 1H);

Mass Spectrum: M+H⁺ 529 and 531; Elemental Analysis: Found C, 57.0; H, 5.71; N, 15.7;

C₂₅H₂₉ClN₆O₅ requires C, 56.8; H, 5.5; N, 15.9%.

- 5 [7] The reactants were 7-(2-chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxyquinazoline and (3RS,4SR)-3,4-methylenedioxypyrrolidine. The reaction mixture was heated to 95°C for 3 hours. The reaction product was purified by column chromatography on a C18 reversed phase silica column (Waters Symmetry column, 5 microns silica, 19 mm diameter, 100 mm length) using a decreasingly polar mixture of
10 water and acetonitrile (containing 1% acetic acid) as eluent. The organic solvents were evaporated and the pH of the aqueous phase was adjusted to 7. The solution was extracted with methylene chloride and the organic phase was dried over magnesium sulphate and evaporated. The resultant residue was triturated under diethyl ether to give the required product in 64% yield which gave the following characterising data; NMR Spectrum: (CDCl₃)
15 1.55 (d, 6H), 2.35 (m, 2H), 2.9 (t, 2H), 3.25 (d, 2H), 4.25 (t, 2H), 4.6 (m, 2H), 4.85 (m, 1H), 4.9 (s, 1H), 5.15 (s, 1H), 6.15 (s, 2H), 6.55 (s, 1H), 6.85 (s, 1H), 7.75 (s, 1H), 8.6 (s, 1H), 9.6 (s, 1H); Mass Spectrum: M+H⁺ 516 and 518; Elemental Analysis: Found C, 54.7; H, 5.2; N, 13.2; C₂₄H₂₆ClN₅O₆ 0.5H₂O requires C, 54.9; H, 5.2; N, 13.3%.

CLAIMS

1. The use of an anti-angiogenic agent in combination with an inhibitor of the Src family of non-receptor tyrosine kinases in the manufacture of a medicament for use in the treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis characterised in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.
- 10 2. The use of an anti-angiogenic agent in combination with a Src kinase inhibitor according to claim 1 in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.
- 15 3. The use of an anti-angiogenic agent in combination with a Src kinase inhibitor according to claim 2 characterised in that :-(
 - (i) an improved anti-cancer effect is obtained comprising both an anti-angiogenic and an anti-invasive effect; and
 - 20 (ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.
- 25 4. The use according to claim 2 of an anti-angiogenic agent in combination with a Src kinase inhibitor in the manufacture of a medicament for use in the prevention or treatment of solid tumour disease characterised in that :-(
 - (i) an improved anti-tumour effect is obtained comprising both an anti-angiogenic and an anti-invasive effect; and
 - 30 (ii) an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

5. The use according to claim 4 of an anti-angiogenic agent in combination with a Src kinase inhibitor wherein the anti-angiogenic agent is an inhibitor of VEGF receptor tyrosine kinases.
- 5 6. The use according to any of claims 1 to 5 of an anti-angiogenic agent in combination with a Src kinase inhibitor wherein the anti-angiogenic agent is described in International Patent Applications WO 00/47212 and WO 01/32651 and in co-pending International Patent Application No. PCT/GB/03/00343.
- 10 7. The use according to any of claims 1 to 6 of an anti-angiogenic agent in combination with a Src kinase inhibitor wherein the Src kinase inhibitor is described in International Patent Applications WO 01/94341, WO 02/16352, WO 02/085895, WO 02/092577, WO 02/092578 and WO 02/092579 and in co-pending European Patent Application No. 02292736.2.
- 15 8. The use according to claim 2 of an anti-angiogenic agent in combination with a Src kinase inhibitor in the manufacture of a medicament for chronic administration in the production of an anti-cancer effect.
9. The use according to claim 5 of an inhibitor of VEGF receptor tyrosine kinases in combination with a Src kinase inhibitor in the manufacture of a medicament for chronic administration for use in the prevention or treatment of solid tumour disease wherein the inhibitor of VEGF receptor tyrosine kinases and the Src kinase inhibitor each possess one or more of the following pharmacokinetic parameters :-
- 20 (i) Compound Clearance of less than about 75% of hepatic blood flow;
- 25 (ii) a Volume of Distribution of less than about 30 L/kg;
- (iii) a bioavailability of more than about 20%; and
- (iv) an elimination half life in the range of about 0.2 to 15 hours.
10. The use according to claim 1 of an anti-angiogenic agent in combination with a Src kinase inhibitor wherein the anti-angiogenic agent is selected from :-
- 30 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
- 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

- 4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-
5 4-yl)methoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-
1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-
10 4-yl)ethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(2-fluoro-4-methylanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
15 4-(2-fluoro-4-methylanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylsulphonylpiperazin-
1-yl)propoxy)quinazoline,
4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)piperazin-
20 1-yl]propoxy}quinazoline,
7-{2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
6-methoxyquinazoline,
4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-
1-yl]propoxy}quinazoline,
25 7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
6-methoxyquinazoline,
7-[3-(4-acetylpirazin-1-yl)propoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
7-(3-(4-acetylpirazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-
6-methoxyquinazoline, and
30 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
6-methoxyquinazoline,
or pharmaceutically-acceptable acid-addition salts thereof.

11. The use according to claim 1 of an anti-angiogenic agent in combination with a Src kinase inhibitor wherein the anti-angiogenic agent is selected from :-
- 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
- 5 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
10 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
- 15 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy}quinazoline,
7-{2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-
6-methoxyquinazoline,
4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]propoxy}quinazoline,
- 20 1-yl]propoxy}quinazoline,
7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-
6-methoxyquinazoline,
7-(3-(4-acetyl)piperazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-
6-methoxyquinazoline, and
- 25 7-[2-(4-acetyl)piperazin-1-yl]ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-
6-methoxyquinazoline;
or a pharmaceutically-acceptable acid-addition salt thereof.

12. The use according to claim 1 of an anti-angiogenic agent in combination with a Src kinase inhibitor wherein the Src kinase inhibitor selected from :-
- 30 4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,

- 4-(2,4-dichloro-5-methoxyanilino)-7-(2-morpholinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 5 4-(2-bromo-5-methoxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-ylethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-
- 10 4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 15 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline,
- 20 6-methoxy-4-(2,3-methylenedioxyanilino)-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline,
- 25 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)quinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]-6-methoxyquinazoline,
- 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,
- 30 4-(2-bromo-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,

- 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline,
- 5 7-[2-(4-acetyl

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,

7-[2-(4-acetyl

10 5-isopropoxyquinazoline and

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-isopropoxyquinazoline;

or a pharmaceutically-acceptable acid-addition salt thereof.

15 13. The use according to claim 1 of an anti-angiogenic agent in combination with a Src kinase inhibitor wherein the Src kinase inhibitor selected from :-

4-(2,4-dichloro-5-methoxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,

4-(2,4-dichloro-5-methoxyanilino)-7-(2-morpholinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,

20 4-yloxyquinazoline,

4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-yloxy)-5-tetrahydropyran-4-yloxyquinazoline,

4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazoline,

25 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methyl

4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,

4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-acetyl

30 5-isopropoxyquinazoline,

6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,

6-methoxy-4-(2,3-methylenedioxyanilino)-7-[3-(4-methyl

- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)quinazoline,
4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]-
6-methoxyquinazoline,
4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
5 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-
4-ylmethoxy)quinazoline,
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline,
7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
10 5-tetrahydropyran-4-yloxyquinazoline,
4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-
3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
5-isopropoxyquinazoline and
15 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-isopropoxyquinazoline;
or a pharmaceutically-acceptable acid-addition salt thereof.

14. A kit for use in dosing the combination defined in claim 1 or claim 2 comprising :-
20 a) an anti-angiogenic agent together with a pharmaceutically-acceptable excipient or carrier, in a first unit dosage form;
b) a Src kinase inhibitor together with a pharmaceutically-acceptable excipient or carrier, in a second unit dosage form; and
c) container means for containing said first and second dosage forms; and characterised
25 in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.

15. A combination product comprising an anti-angiogenic agent selected from :-
30 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-
1-yl)propoxy)quinazoline,

- 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
- 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
- 5 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,
- 4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]propoxy}quinazoline,
- 7-(3-(4-acetylpirazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline and
- 10 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline,
or a pharmaceutically-acceptable acid-addition salt thereof;
- and a Src kinase inhibitor selected from :-
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-pyrrolidin-1-yloxy)-5-tetrahydropyran-
- 15 4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-(3-pyrrolidin-1-ylpropoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpirazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 20 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline,
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline,
- 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline,
- 25 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-piperidinopropoxy)quinazoline,
- 4-(6-chloro-2,3-methylenedioxyanilino)-7-[3-(4-isobutyrylpiprazin-1-yl)propoxy]-6-methoxyquinazoline,
- 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline,
- 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
- 30 5-tetrahydropyran-4-yloxyquinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,

7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
5-isopropoxyquinazoline and

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-

7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl)ethoxy]-5-isopropoxyquinazoline,

5 or a pharmaceutically-acceptable acid-addition salt thereof;

for use in the production of an anti-cancer effect in a warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

10

16. A pharmaceutical composition comprising a combination product according to claim 15 and a pharmaceutically-acceptable excipient or carrier.

17. A kit for use in dosing a combination product according to claim 15 to produce an anti-cancer effect in a warm-blooded mammal such as a human being comprising :-

a) an anti-angiogenic agent together with a pharmaceutically-acceptable excipient or carrier in a first unit dosage form;

b) a Src kinase inhibitor together with a pharmaceutically-acceptable excipient or carrier in a second unit dosage form; and

20 c) container means for containing said first and second dosage forms; and characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

25 18. A combination product according to claim 15 comprising the anti-angiogenic agent 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, and the Src kinase inhibitor 7-[2-(4-acetylpirazin-1-yl)ethoxy]-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, for use
30 in the production of an anti-cancer effect in a warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination product is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination product are substantially counter-balanced.

A B S T R A C TTITLE : THERAPEUTIC AGENT

5

The invention relates to the use of an anti-angiogenic agent in combination with an inhibitor of the Src family of non-receptor tyrosine kinases in the manufacture of a medicament for use in the production of an anti-angiogenic and an anti-cancer effect in a
10 warm-blooded mammal such as a human being characterised in that an appropriate dose of each component of the combination is selected such that the contrasting blood pressure effects associated with the individual use of either component of the combination are substantially counter-balanced.


Figure 1

Figure 1/3 effect of VTK-1 on rat diastolic blood pressure

101046

2/3

Figure 2




Figure 2/3 effect of Src-1 on rat diastolic blood pressure


Figure 3

Figure 3/3 effect of combination of VTK-1 and Src-1 on rat diastolic blood pressure

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLORED OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox